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ABSTRACT OF THE DISSERTATION
SAB CONCENTRATION DETERMINES THE CHEMOTHERAPEUTIC EFFICACY
IN GYNECOLOGICAL CANCER
by
Iru Paudel
Florida International University, 2018
Miami, Florida
Professor Jeremy W. Chambers, Major Professor

The American Cancer Society predicts there will be 110,070 new cases and 32,120 deaths
due to gynecological malignancies in 2018. A major contributing factor to the high
mortality associated with gynecological cancers is the recurrence of treatment-resistant
tumors. Ovarian cancer (OC) remains the most lethal gynecological malignancy, yet the
mechanisms responsible for regulating tumor resistance and vulnerability are largely
unknown or undruggable. Therefore, the goal of this research is to identify mechanisms
responsible for therapeutic resistance in gynecological cancers and discover innovative
approaches to circumvent these molecular alterations. Our efforts began in OC where
secondary analysis of gene expression data from OC studies revealed that Sab, an outer
mitochondrial membrane (OMM) scaffold protein, was down-regulated in OC tumors
compared to normal tissue controls. Our previous studies demonstrate that Sab-mediated
OMM signaling induces cell death in cervical cancer. In the current study, we found that
Sab concentrations corresponded to chemoresponsiveness in a panel of OC cells; wherein,
OC cells with low Sab levels were chemoresistant. Dynamic BH3 profiling revealed that
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cells with high Sab expression were primed for apoptosis. Furthermore, over-expression of
Sab in chemoresistant cells enhanced apoptotic priming and restored cellular vulnerability
to cisplatin/paclitaxel treatment. Additionally, an examination of treatment-resistant
metastatic uterine cancer (UC) cells were found to have low Sab concentrations compared
to vulnerable primary site-derived UC cells. Ectopic expression of Sab in chemoresistant
UC cells enhanced the susceptibility towards megestrol acetate and BH3-mimetic ABT737. To exploit the relationship between Sab concentrations and chemo-responsiveness in
gynecological cancer cells, we developed a high-throughput screening assay to detect Sab
levels in chemo-resistant OC cells. In collaboration with the Torrey Pines Institute for
molecular studies, we have identified compounds that can increase Sab levels in resistant
OC cells. The identified compounds improved the effectiveness of cisplatin/paclitaxel
therapy. We propose that Sab may be a prognostic marker to discern personalized
treatments for gynecological cancer patients. Furthermore, pharmacologically enhancing
Sab-mediated signaling may increase the efficacy of chemotherapeutic agents, which
would mean lower doses that would limit toxic side-effects.
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Chapter 1
LITERATURE REVIEW

1

Gynecological cancer
Five different types of cancer arise within the reproductive organs of women are termed
together as gynecological cancer. These include cervical, ovarian, uterine, vaginal and
vulval cancers. Each gynecological malignancy is uniquely characterized by different
diagnostic signatures, symptoms, and pathogenesis (CDC). The projected statistics for
gynecological cancer for 2018 is enlisted in table 1.1 [1]. Ovarian cancer is the most lethal
gynecological malignancy [2], and we will focus mostly on it.
1. Ovarian Cancer
1.1. OC Statistics: Ovarian cancer (OC) is the gynecological malignancy with the greatest
mortality. OC accounts for approximately 4% of all cancer in the women and is the seventh
most common cancer worldwide [2]. In the United States, according to American Cancer
Society (ACS), the estimated number of new cases of OC in 2017 was 22,440, and the
estimated number of deaths was 14,080. The overall five-year survival rate for OC is 46.5%
(2007-2013). In a woman’s lifetime, the risk of developing an invasive form of OC is 1 in
79, and the resulting risk of death is 1 in 109 [2]. These statistics demonstrate gravity
associated with OC and the demand for better treatment.
Table 1.1: Gynecological cancer statistics
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1.2. Clinical Stages of OC: For effective treatment, OC is divided into different stages based
on how far it has spread and what organs are affected in patients. It is called the FIGO
(Federation of Gynecological Oncologists) system.
A. Stage 1: The cancer is confined to the ovaries (primary site tumors).
B. Stage 2: Cancerous cells have gone beyond ovaries, it has spread to the pelvis
and sometimes even to the abdomen.
C. Stage 3: Cancer has crossed the pelvis and spread to the abdominal cavity
D. Stage 4: Cancer has spread to distant organs like liver and lungs.
The staging may also be classified as local (referred as stage 1 and confined to primary
sites), regional (spread to regional lymph nodes), distant (cancer has metastasized) and
unknown. Approximately,14.8% of OC are diagnosed at the local stage, and the five-year
survival for these patients is 92.5%. However, 60% of women in the United States are
diagnosed with late-stage OC. More than half of the patients diagnosed with late-stage OC
will relapse within 18 months after initial therapy [3].
1.3. Types of OC: OC is classified into three types based on the etiology of the malignancy:
epithelial ovarian cancer (EOC), germline ovarian cancer and stromal cell ovarian cancer
[4]. EOC is the most common and highly heterogeneous form of ovarian cancer [4].
Histologically EOC can be further divided into different subtypes; the four most common
includes Serous, Endometroid, Mucinous and Clear Cell carcinoma [5]. Histological
classification of OC is based on the tumor cell origin and morphology [6].
1.3.1. Serous ovarian carcinoma (SOC): Serous carcinomas are considered to develop from
ovarian surface epithelium or inclusion cysts [7]. SOC comprise most ovarian carcinomas
and are further classified into low-grade and high-grade. Low-grade carcinomas are less
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common than high-grade. The high grade and low-grade carcinomas are characterized by
different underlying pathogeneses, molecular events, behavior and prognosis [8]. These
two are distinguished based on morphology, the degree of nuclear atypia (abnormal
appearance of cell nuclei), and the amount of mitotic activity. Low-grade serous
carcinomas have mild to moderate nuclear atypia with less than 12 mitoses per 10 highpower field images. High-grade have, in contrast, nuclear atypia greater than 12 mitoses
per 10 high-power field images [8]. In both grades of serous carcinomas, diverse cellular
architectural patterns, such as nested, papillary, glandular, cribriform, solid and single can
be present. Laminated psammoma bodies are usually present in both tumor types [8].
1.3.2.Mucinous ovarian carcinomas (MOC): These are the less common type of ovarian
carcinomas, only 5-10% of EOC [9]. Mucinous carcinomas are of so-called intestinal or
enteric subtype with cystic unilocular neoplasm with a thin space wall and filled with
watery mucinous fluid. MOCs are confined to the ovary at diagnosis. They have solid and
necrotic areas which histologically may be borderline or malignant [10]. MOCs have the
worst prognosis and poor response to chemotherapy compared to other subtypes [11].
1.3.3.Endometroid ovarian carcinoma: Endometroid carcinomas have been reported to
develop from endometriotic tissues [12]. Endometroid carcinomas are commonly
characterized by an epithelium composed of single layer of large polygonal cells with
abundant eosinophils and large hyperchromatic, smudged nuclei [10,12]. Advanced
endometroid carcinoma normally responds to platinum-taxane combination treatment.
However, the relapse rate is high with poor prognosis [13].
1.2.4.Clear cell carcinoma: This is a rare epithelial ovarian carcinoma which makes less
than 10% of EOC [10,12]. They are characterized by a clear peg-shaped cell with abundant
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cytoplasm. The cells can be observed either alone or in combination [10]. Clear cell
carcinomas are usually chemoresistant malignancies with a poor prognosis [14].
1.4. Common OC features: Cancers cells are typified by the occurrence of ten traits,
which are termed hallmarks of cancer. OC hallmarks include the capabilities for sustaining
proliferative signaling, resisting cell death, evading growth suppressors, activating
invasion and metastasis, enabling replicative immortality, inducing angiogenesis, avoiding
immune destruction, tumor-promoting inflammation, genome instability, and mutation and
deregulating cellular energetics [15]. These features allow cancer cells to survive,
proliferate, and disseminate. In addition to these hallmarks, tumors have other
characteristics like evading immune destruction, the presence of genomic instability and
mutation, and reprogramming of energy metabolism. Somatic mutations in the ovarian
tumors, which can activate downstream pathways; for example, mutations in the BRAF
proto-oncogene can engage mitogen-activated protein kinase (MAPK) signaling pathways.
Alterations in MAPK pathways are observed during cancer progression. Inhibition of the
c-Jun N-terminal Kinase (JNK)-induced apoptotic death is one of the mechanisms
developed during OC [16]. Tumors have a complex environmental dynamics including the
presence of heterogeneous cell populations. This includes the cells that make up the tumor
and those in the surrounding tumor microenvironment, wherein both areas play a
significant role in tumor development and progression. Normal cells, including immune
cells, may contribute to tumorigenesis by providing various growth factors to tumors [15].
The cell types and tumor microenvironment are crucial to the development and outcomes
of individual tumors including tumor size and therapeutic resistance.
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The hallmarks of cancer are present in OC, and these hallmarks represent potential, enticing
targets for OC drug discovery. Metastasis is one crucial hallmark, which accounts for the
high morbidity and mortality by OC because the spread of the tumor beyond ovaries
increases the difficulty of treating cancer [17]. There are two prevailing reasons behind the
absence of an effective treatment for OC: late diagnosis and resistance to available
therapeutic approaches [3]. Complicating the difficulties in treating OC is the fact that the
origins and pathogeneses of OCs are poorly understood. There are numerous treatment
options available for the attempted management of OC; however, each one has its benefits
and drawbacks. For example, radiation targets specifically the cancer cells; however, it
damages the DNA of cells instead of killing cells while chemotherapy is given to entire
body and kills cancer as well as other dividing cells. The most prominent problem with OC
treatment is its relapse or recurrence because of the return of the disease following
treatment is typified by the presence of highly resistant tumor cells. One important cause
of characteristic of these resistant cells is their ability to withstand a variety of cell death
mechanisms. The heterogeneous cell population and absence of a prevailing cell death
pathway are evidence of the urgent need for novel and aggressive therapies for OC [17].
1.5. OC chemotherapy mechanisms of action and the involvement of JNK signaling
The standard of care for OC patients is the combination of surgery and radio/chemotherapy
[18]. Surgery removes the local tumor mass (or those that are visible) [19], and surgery
may be followed by a chemotherapeutic regimen comprised of a platinum-based
compound, such as cisplatin, and a taxane, like paclitaxel [17]. Based on individual
responses to chemotherapy, OC patients are classified into platinum-sensitive (recurs after
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six months of treatment), platinum-resistant (recurs within six months after treatment) and
platinum-refractory (recurs during treatment) [17].
Platinum compounds, like cisplatin and carboplatin, form active species by aqueous
hydrolysis(i.e., these compounds react with water and form reactive species). These species
can interact with DNA, RNA, and proteins. Most of the cytotoxic effects of platinum
compounds result from the formation of DNA inter-stand and intra-stand crosslinks
because these disturb DNA replication. Consequently, the cell engages repair processes
such as nucleotide-excision repair (NER) and mismatch repair (MMR) [20]. NER solely
repairs the damage, whereas MMR can induce apoptosis in addition to repair. It has been
observed that in response to cisplatin, MMR-related signaling pathways; specifically, cAbl protein tyrosine kinase and JNK are activated. In the cells lacking MMR, both
signaling pathways are not initiated [21]. This evidence suggests that JNK is involved in
cisplatin-induced cell death. Further studies reveal that sustained activation of JNK
pathway by cisplatin occurs in the OC cell line 2008, while in its cisplatin-resistant clone
2008c13 did not display JNK activation [22]. This suggests that a failure to robustly induce
apoptotic signaling may be a contributing factor to platinum resistance in OC.
Taxols act by binding to -tubulin of microtubules causing microtubule stabilization,
leading to cell cycle arrest (specifically arresting cells at G2-M) and ultimately apoptosis
[23]. Paclitaxel regulates MAPK signaling and promotes phosphorylation of Bcl-2 and
dephosphorylation of Bad triggering apoptosis [24] Additional research suggests that
paclitaxel promotes apoptosis in OC cells. Woo et al., demonstrate that JNK activity
contributes to paclitaxel-induced apoptosis [25]. Further, the Ras-related nuclear protein
(Ran) impairs JNK-mediated phosphorylation in U373MG cells preventing the
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phosphorylation of downstream pro-apoptotic Bcl-2 proteins and induction of apoptosis
[25]. Additionally, Lee and colleagues show that JNK is phosphorylated after paclitaxel
exposure in a dose-dependent manner before cell death [26]. These studies collectively
fundamentally implicate JNK in chemotherapy-induced apoptosis in OC cells.
2. Uterine/Endometrial Cancer
Uterine or endometrial cancer is the fourth most common cancer in the United States.
Endometrial cancer is the most commonly diagnosed gynecological malignancy. ACS
estimates 63,230 new cases and 11,350 death from the cancer of uterine body in 2018. The
5-year survival for uterine cancer is 82% [1]. It is the sixth most common cause of cancer
death among women in the USA [2]. The most common treatment approach for
endometrial cancer is surgery [27], and it has been found to be effective for tumors confined
to the uterus [28]. However, surgery alone cannot treat advanced or recurrent endometrial
cancer. A combination of radiotherapy with platinum-based chemotherapy is employed for
progression-free survival in endometrial cancer [29].
3. Cervical Cancer
Cervical cancer is caused by the development of cancer in the uterine cervix. ACS
estimates 13,240 new cases and 4,170 deaths from the cancer of the cervix in 2018.
Cervical cancer is the second leading cause of cancer death in women aged 20 to 39 years
[1]. The prognosis of the cervical cancer patient with an advanced or metastatic
malignancies is poor. A common form of treatment is surgery followed by cisplatin or
carboplatin. Cisplatin-paclitaxel combination may be an improved chemotherapeutic
modality for advanced cervical cancer [30]. Bevacizumab is a humanized vascular
endothelial growth factor (VEGF)- neutralizing antibody, and the addition of bevacizumab
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to combination chemotherapy increases disease-free survival in cases of advanced or
metastasized cervical cancer [31].
4. c-Jun N-terminal kinase (JNK)
Mitogen-activated protein kinases (MAPKs) are critical modulators of numerous cellular
processes, namely proliferation, differentiation and apoptosis [32]. JNK is a member of the
MAPK superfamily and is an effector kinase. JNK has a profound impact on cellular
viability, as it is a critical regulator of apoptosis. JNK is a serine/threonine (Ser/Thr) protein
kinase that modulates cell survival pathways by targeting transcription factors and other
non-nuclear substrates [32-34]. JNK activation and function is regulated by phosphorelay
cascade (Figure 1.1). JNK activation occurs in response to both extracellular and
intracellular stimuli, which may influence JNK function in a cell and stress-dependent
manner by activating specific MKKKs. These MAPKKKs, in turn, activate two MAPKKs,
MKK7 and MKK4. MKK7 and MKK4 phosphorylate JNK on threonine 183 (Thr183) and
tyrosine 185 (Tyr185) of the activation loop respectively [32,34]. Although
phosphorylation of both sites is required for full activation, it is suggested that Thr183 is
the critical residue and Tyr185 gives fine tuning in TNF-α induced JNK activation [35].
Active JNK then phosphorylates downstream substrates, such as c-Jun, ATF-2, c-Myc,
p53, and Bcl-2 proteins; this protein alteration determines the biological outcomes of
specific stimuli [32,33,36].
The role of JNK in apoptosis is well-established [32,37], and JNK-mediated apoptosis has
been observed in numbers of stresses including anisomycin, dexamethasone, phorbol ester,
acetaminophen-induced liver injury, DNA damaging agents, paclitaxel and in disease
models of cardiac stress, cerebral ischemia, and aging [26,38-44]. JNK-mediated apoptosis
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was first identified in rat PC-12 pheochromocytoma cells following nerve growth factor
(NGF) withdrawal. This apoptotic cell death was suppressed by inhibition of JNK pathway
by using dominant negative form of the JNK substrate c-jun.

Figure 1.1: JNK phosphorylation and activation occurs in response to the activation of
upstream kinases, MKK and MKKK. In response to different signals, the upstream kinase
MKKK gets phosphorylated, which phosphorylates MKK7 and MKK4. MKK7/4 activation causes
the phosphorylation of JNK. JNK activation can lead to nuclear-JNK or mitochondrial-JNK
signaling depending on the signal and cell type.

Further, constitutively active mitogen-activated protein kinase kinase kinase 1 (MEKK1)
induced apoptosis, implicating JNK as a pro-apoptotic kinase [45]. Additionally, genetic
ablation of JNK prevents apoptosis as well. Hippocampal neurons in JNK3-/- mice were
resistant to kainic acid-induced apoptosis [46]. Suppression of cell death in response to
ultra-violet light and anisomycin in JNK1-/- JNK2-/- and MKK4-/- MKK7-/- mouse embryonic
fibroblasts (MEFs) also demonstrate the significance of JNK in apoptosis [35,47]. It was
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shown that the absence of JNK prevented the release of cytochrome c from the
mitochondria, in JNK1-/- JNK2-/- MEF following UV exposure; while cytochrome c release
was observed in WT-MEF (wild-type). Again demonstrating JNK as an important
component of the mitochondria-mediated apoptosis [47]. Recently, the interaction of JNK
with mitochondrial scaffold protein Sab (or SH3-binding protein 5 – SH3BP5) during
stress was revealed to have a significant impact on apoptosis; the association of JNK with
Sab promotes JNK-mediated phosphorylation of anti-apoptotic protein Bcl-2 on Ser-70.
JNK phosphorylation of Bcl-2 leads to emigration of the protein from the outer
mitochondrial membrane (OMM) ultimately promoting apoptosis [48].
Despite an abundance of data implicating JNK in apoptosis, other studies suggest JNK
signaling may have pro-survival functions. JNK can facilitate IL-3-mediated survival of
hematopoietic pro-B FL5.12 cells [49]. JNK generates this survival response by
phosphorylating and inactivating pro-apoptotic protein Bad at Thr-201; inhibition of JNK
caused an increase in IL-3 withdrawal-induced apoptosis. Meanwhile, expression of a
constitutively active MEKK1 suppressed cell death [49]. Sabapathy et al., have shown both
the pro-apoptotic and anti-apoptotic role of JNK in the development of fetal brain using
JNK1-/- JNK2-/- double knockout fetuses. JNK1 and JNK2 positively regulate apoptosis in
hindbrain region at E9.25 (embryonic day); whereas, there was a decrease in apoptosis in
the double-knockout animals. The overall effect of the double-knockout is defective neural
morphogenesis and defective neural tube closure [50]. Inhibition of cell proliferation and
inhibition of cell cycle progression was observed in cultured KB-3 human cells with JNK
inhibitor (SP600125), and JNK-specific anti-sense oligonucleotides, supported the role of
JNK in cellular proliferation [51]. Thus, JNK activity can be a pro-apoptotic and a pro-
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survival kinase, depending on the stress, physiologic conditions, localization, and
potentially the activity of distinct JNK isoforms.
The involvement of mitochondrial JNK signaling in improving the chemotherapeutic
efficacy in gynecological cancer was observed following low-dose sub-chronic
administration of LY294002 in HeLa cells (cervical cancer) [52]. The prolonged exposure
of HeLa cells to LY294002 increases phospho-JNK (active kinase) on the mitochondria of
HeLa cells [52]. Blocking the accumulation of JNK on mitochondria was found to reduce
the sensitivity of HeLa cells towards common chemotherapeutic agents [52].
Mitochondrial JNK also regulates mitochondria-mediated intrinsic apoptosis by regulating
Bcl-2 family of proteins [53]. These studies demonstrate that mitochondrial JNK may be a
crucial driver of apoptosis in cancer cells.
5. Bcl-2 superfamily of proteins
B-cell lymphoma-2 (Bcl-2) family of proteins includes both pro-survival and pro-apoptotic
proteins with a profound impact on cell death and survival. This family of proteins has four
domains BH1, BH2, BH3 and BH4; and subfamilies are identified by the specific domains
that are present within the proteins (Figure 1.2). Anti-apoptotic or pro-survival Bcl-2
proteins have all four BH domains and include, Bcl-2, Bcl-xL, Mcl-1, Bcl-w, Bcl-B, Bfl1/A1. Pro-apoptotic Bcl-2 proteins are further divided into pro-apoptotic BH3 only proteins
and multi-domain proteins. BH3 only pro-apoptotic proteins include Bid, Bad, Bim, Bmf,
Bik, Hrk/DP5, Blk, Nip3, BNip3/Nix, Puma, Noxa. These proteins assist the executor
proteins in apoptosis and sequester anti-apoptotic proteins (Figure 1.3). Bid and Bim act as
major ‘direct activators’ which are responsible for the induction of activation of Bax and
Bak via their BH3 domain whereas Bad and Puma are also called sensitizers or de-
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repressors, because of their ability to bind anti-apoptotic protein [54,55]. Multi-domain
proteins have BH1, BH2, and BH3 domains. These are executor apoptotic proteins and are
also called effectors, which include Bax, Bak, and lesser known protein Bok [56,57].
Bax and Bak’s oligomerization leads to MOMP (mitochondrial outer membrane
permeabilization), pore formation and release of cytochrome c and other factors into the
cytoplasm. This ultimately starts the cell death process by activating apoptotic protease
activating factor-1 (APAF-1) which further stimulates caspases [58].

Figure 1.2: Bcl-2 family of proteins with specific domains. Anti-apoptotic proteins have all four
domains (BH1, BH2, BH3 and BH4), whereas BH-3 only pro-apoptotic have BH3 domain, and
effector proteins have three domains (BH1, BH2, and BH3).

5.1. Interaction between Bcl-2 proteins
Bcl-2 family is classified into two groups, folded globular and intrinsically unstructured
proteins (IUPs). Globular proteins, which include antiapoptotic and effector protein, share
a core structure of the protein called ‘Bcl-2 core’. The first study of the structure of these
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proteins was done in Bcl-xL, which is a 20KD globular protein, using NMR based
spectroscopy and X-ray crystallography[59]. Three-dimensional structure of ‘Bcl-2 core’
contains seven or eight amphipathic alpha helices, surrounding central helix, α5 and α6.
Both helices are highly hydrophobic and are flanked by α3 and α4 on one side and α1 and
α2 on the other. This hydrophobic groove is termed as BC groove. The BH4 (conserved α1
positioned along α6) domain stabilizes BH1-BH3 regions. BC groove and α1/α6 makes up
the ‘Bcl-2 core’[60,61].
The hydrophobic groove is the interaction site of anti-apoptotic proteins and BH3 domain
of both the effector and BH3 only proteins, which was first observed between Bcl-xL and
Bak. This interaction was detected by co-immunoprecipitation and two-hybrid interaction
in the yeast; which was supported by NMR spectroscopy between Bcl-xL/Bak peptide
complexes. Heterodimerization was observed, which was because of electrostatic and
hydrophobic interaction between these two proteins [56]. Mutation on BH3 domain led to
the termination of this interaction which suggests that there is conserved amino acid in the
BH3 domain.
The BH3 domain consists of between 9 and 16 amino acids, of which seven were found to
by core amino acids by phylogenetic studies. The sequence is LXXXXGDE, where X is
any amino acid [62]. Recently, a 13-residue consensus motif has been proposed based on
structural

studies

and

sequence

analysis.

The

consensus

motif

is

Ф1ΣXXФ2XXФ3Σ’DZФ4г; where Ф represents a hydrophobic residue (Ф2 is often
leucine), Σ is a small residue (G, A, S), Z is usually an acidic residue and г is a hydrophilic
residue [63]. The most conserved residues are leucine and aspartic acid residues which
have an important role in interaction with the anti-apoptotic protein. The leucine residue is
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buried in the protein-protein interface and packs against the conserved residue of antiapoptotic protein whereas aspartate forms ionic interaction with conserved arginine in the
BH1 domain of pro-survival protein [56,64]. Other binding interactions like Vander Waals,
hydrophobic and hydrophilic interaction play equally important role [63].
As different BH3 proteins have diverse amino acids in their BH3 domains, this could be
affecting their binding preference for anti-apoptotic proteins. In vitro analysis was
performed using recombinant anti-apoptotic proteins and synthetic BH3 peptides of the
BH3 only protein to determine the binding specificity of this BH3 only proteins. This
revealed that there is preference shown by BH3 domains for binding anti-apoptotic proteins
[65]. Among eight BH3 peptides, BIM and Puma had the affinity for all the anti-apoptotic
Bcl-2 proteins whereas others were specific. It could be said that the observed selectivity
was relying on the BH3 motif; any mutational change could change the specificity easily
[66].
5.2. Bax activation
While there are many BH3-only proteins having the ability to bind to anti-apoptotic
proteins, only few can bind to effector pro-apoptotic proteins. Activators BH3 proteins,
Bim and Bid, can induce oligomerization of Bax and Bak, OMMP formation and
cytochrome c release [67].
Bid also has the affinity for anti-apoptotic Bcl-2 and Bcl-xL. There are two different
theories for activation of Bax by Bid. Bid can either directly activate full-length Bax or tBid, a cleaved form of Bid activates Bax differently. t-Bid has been described as the direct
activator of Bax. However, the exact mechanism of Bax activation was not clear. Bid can
be cleaved by caspase 8 forming t-Bid, which is unable to interact with full-length Bax or
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Bcl-xL in solution [68]. Following cleavage, N-terminus Bid (N-Bid) remains attached
with C-terminus Bid (C-Bid), forming BH3 domain. In the presence of lipid bilayer;
mimicking OMM, C-Bid inserts into the membrane, while the N-Bid remains in the
solution. Once in the membrane, it can recruit Bax into the membrane, which was shown
by fluorescence resonance energy transfer (FRET) [68]. This emphasizes the importance
of lipid membrane for Bax activation. tBID also can cause an allosteric conformational
change of Bak followed by its homo-oligomerization and the release of cytochrome c [69].
To understand the mechanism of Bax activation by Bid, the α-helix of Bid was stabilized
by a chemical modification called ‘hydrocarbon stapling’ [70]. The C terminal α-helix 9 of
Bax is embedded into the hydrophobic groove, making it problematic for BH3 protein
binding; as this is the site where BH3 domain binds to the anti-apoptotic protein [71]. With
the modification of BH3 Bid helix, it could bind to the groove by displacing intramolecular
Bax α-helix. This led to the conformational change of Bax and cytochrome c release was
observed in both in vitro and in vivo experiments. A similar result was observed with the
modification of Bim peptide. However, modified Bad BH3 didn’t show any ability to bind
Bax [70]. According to the NMR studies, Bax interaction with Bim causes the
conformational change in α-helix 1 & 2, from closed to an open conformation which causes
the release of α-helix 9 hydrophobic grooves exposing the groove for BH3 binding [72].
5.3. Bcl-2 proteins: The individual member of the Bcl-2 family will be discussed further
below.
5.3.1. Bcl-2: B-cell lymphoma-2 (Bcl-2) is a 26kD anti-apoptotic protein. Bcl-2 is a
membrane-associated protein embedded in the endoplasmic reticulum, the nuclear
envelope, and the outer mitochondrial membrane [73]. Bcl-2 can be modified by several
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kinases and phosphatases, and these modifications play significant roles in cellular
survival/death [36].

Figure 1.3: BH3 only proteins have multiple roles. They can neutralize the pro-survival proteins
causing the release of Bax and Bak or directly activate effector proteins by a conformational change
of Bax and Bak. Both events lead to the translocation of Bax to OMM, oligomerization with
mitochondria located Bak, which eventually causes OMM permeabilization, the release of
cytochrome c and initiation of apoptosis.

The microtubule damaging agent, paclitaxel induces phosphorylation of Bcl-2 in
unstructured loop regions where residues Ser70, Ser87, and Thr69 were phosphorylated in
Jurkat-Bcl-2 cells [36]. This is further supported by other observations where deletion of
Bcl-2 loop regions completely blocked paclitaxel-induced apoptosis [74,75]. Mutations of
these sites enhance the anti-apoptotic function of Bcl-2 [36]. Ser-70 is the principal site of
phosphorylation of Bcl-2 during various stress conditions, including paclitaxel, vinblastine,
and anisomycin [48,76,77]. This phosphorylation was found to be mediated by JNK [36].
Ser-70 phosphorylation suppresses the pro-survival function of Bcl-2, and mutation in this
site improves the anti-apoptotic function of Bcl-2 indicating the importance of this site in
Bcl-2 function [36]. In contrast, same site phosphorylation could lead to inhibition of cell
death pathway. JNK-mediated Ser-70 phosphorylation was found to enhance cell survival
during various stress conditions including IL-3 withdrawal and a low dose of okadaic
treatment in murine wild-type [78].
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With the treatment of paclitaxel, the active form of JNK (Phospho-Thr-Tyr) and
phosphorylated Bcl-2 (Ser-70) were found in the mitochondria of HeLa (cervical cancer)
and MCF-7 (breast cancer) cells. This was also observed in cell-free mitochondria when
treated with cytosolic activated JNK, which was extracted from HeLa cell treated with
paclitaxel. Preincubation of a cytosolic extract from paclitaxel-treated HeLa cells with
CEP11004, a proposed JNK inhibitor, did not show any phosphorylation of Bcl-2 [79].
Conversely, Park et al. have shown the regulation of JNK1 activity by Bcl-2 protein.
Apoptosis is activated in N18TG neuroglioma cells in response to various apoptotic
stresses. However, in N18TG cells expressing Bcl-2 (N18 cells transfected with Bcl-2)
were resistant to etoposide, staurosporine, anisomycin, and UV mediated cell death. It was
found that Bcl-2 inhibits the activation of MEKK1, the upstream activator of JNK signaling
pathway [80]. Expression of JNK1 in N18/ Bcl-2 cells neutralized or counteracted the antiapoptotic effect of Bcl-2; making N18/Bcl-2 cells as sensitive as the control cells [80]. Bcl2 was also shown to inhibit the activation of JNK in response to nerve growth factor
withdrawal in PC12 cells [81]. These observations suggest that JNK1 and Bcl-2 protein
can regulate each other depending on the cellular context.
5.3.2. Bcl-xL: B-cell lymphoma extra-large (Bcl-xL) is an anti-apoptotic transmembrane
protein present in the mitochondria. Bcl-xL is a 20kD globular protein and was the first
protein of the family in which structural detail was studied [82]. Bcl-xL can inhibit the
formation of OMMP and release of cytochrome c. Even though many cell lines express
both Bcl-2 and Bcl-xL, an inverse association in the expression pattern of these two
proteins have been found in thirty-four cell lines derived from colon, breast, ovary, central
nervous system, and renal cancers [83].
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Petros and colleagues have suggested that the characteristic feature of Bcl-xL and Bcl-2 to
heterodimerize with Bax, Bak, and other BH3 only proteins keeps the apoptotic balance of
the cells [84]. Letai and colleagues proposed that the antiapoptotic protein binds to the BH3
domain of activator protein and sequesters them before they could activate Bax and Bak
[85].
In response to ionizing radiation, Kharbanda et al. have shown the translocation of JNK to
mitochondria in U-937 (lymphoma) cells, using fluorescence image analyzer, microscopy,
and immunoblotting. At mitochondria, JNK was found to interact with Bcl-xL, which was
shown by a co-localization assay. JNK phosphorylates Bcl-xL on Threonine-47 (Thr-47)
and Threonine 115 (Thr-115) in U-937 cells [86]. Further, the effect of tetradecanoyl
phorbol-13-acetate (TPA) on JNK and Bcl-xL was studied on U-937 cells, where no
significant effect of Bcl-xL was found on the JNK translocation to mitochondria; however,
TPA-induced the interaction of JNK and Bcl-xL. Overexpression of Bcl-xL mutated at
sites of JNK phosphorylation (T47A and T115A) caused a substantial decrease in the
release of cytochrome c and apoptosis compared to the overexpression of normal Bcl-xL;
signifying the importance of these two sites in Bcl-xL function [40]. JNK was also found
to phosphorylate Bcl-xL in 293T cells [86]. JNK mediated phosphorylation in Ser-62,
within the unstructured loop region of Bcl-xL was observed in response to taxol or 2methoxyestradiol in DU145 human prostate cancer cells [87].
Phosphorylation of Bcl-2 and Bcl-xL by JNK has been observed in KB-3 sarcoma cells
following treatment with vinblastine. When JNK-1 and JNK-2 expression were inhibited
using antisense oligonucleotides, there was a decrease in the phosphorylation of Bcl-2 by
85% and Bcl-xl by 65% [76]. Similarly, Du et al. have shown phosphorylation of Bcl-2
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and Bcl-xL with the treatment of vinblastine in KB-3 carcinomas. Even though the
phosphorylation of both proteins was shown to be dependent on the same kinase, they were
not able to identify the kinase responsible. They showed that there was no effect in
phosphorylation event with the use of JNK, ERK and CDK inhibitors [88]. Taken together,
JNK has a significant role in post-translational modification of pro-survival proteins Bcl-2
and Bcl-xL resulting in different outcomes.
5.3.3. Mcl-1: Myeloid cell leukemia-1 (Mcl-1) is a 40kD pro-survival Bcl-2 protein,
expressed in many cell types [61]. Mcl-1 is regulated at the transcriptional, translational
and post-translational level [89,90]. Mcl-1 has an important role in proliferating cells and
early embryonic development [91]. Mcl-1 contributes to pro-survival function by
inhibiting the formation of OMMP and release of cytochrome c, which is done either by
inactivating Bax and Bak or sequestering the BH3 only activator protein Bim [61].
Mcl-1 is regulated by phosphorylation at various sites. Enhancement of the antiapoptotic
function of Mcl-1 occurs when it is phosphorylated at Ser-64 in a cell-cycle-dependent
manner by CDK1, CDK2, and JNK1. Instead of affecting the Mcl-1 turnover, Ser-64
phosphorylation enhances the binding of Mcl-1 to pro-apoptotic Bcl-2 protein. The
requirement of Ser64 phosphorylation of Mcl-1 in TNF-related apoptosis-inducing ligand
(TRAIL)-mediated apoptosis was shown in KMCH cholangiocarcinoma cell by silencing
endogenous Mcl-1 and transfecting with S64A, S64E and wild-type Mcl-1. Cells with
silenced Mcl-1 and S64A were quite sensitive to TRAIL while S64E, which mimics
phosphorylation, and wild-type were resistant [92].
JNK facilitates the UV-mediated degradation of Mcl-1. In wild-type fibroblasts, there was
a significant decrease of Mcl-1 while there was no change in JNK1-/-, JNK2-/- fibroblasts.
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This degradation of Mcl-1 occurs via the GSK-3 mediated proteasomal pathway. JNK
phosphorylates Mcl-1 at Thr-163 and primes Mcl-1 for GSK3 phosphorylation. GSK3
phosphorylates Mcl-1 at Ser-159 leading to its ubiquitination and degradation [90]. Mcl-1
half-life and turn-over rate are regulated by the proteasomal degradation pathway [93,94].
Phosphorylation of Ser-121 and Thr-163 in Mcl-1 by JNK has shown opposing effects in
two different cell lines. In hepatocytes, it stabilizes Mcl-1 whereas, in endothelial cells, it
causes a reduction in the anti-apoptotic effect of Mcl-1 mediated by oxidative damage
[61,95,96]. JNK signaling pathway is involved in phosphorylation of Mcl-1, which could
enhance its pro-survival function or inhibit its pro-survival function and initiate the
degradation of the protein.
5.3.4. Bim/ Bmf: Bcl-2 interacting mediator of cell death (Bim) and the closely related
Bim-related molecule (Bmf) are BH3-only pro-apoptotic proteins that are normally
sequestered by binding to motor complexes. Transcriptional and post-translational
regulation plays an important role in their apoptotic activity [58]. Bim exists in three
isoforms produced as a result of alternative splicing; BimS (short isoform), BimL (long
isoform) and BimEL (extra-long isoform) [97]. BimL and BimEL are present in normal
cells while BimS is transiently present in cells undergoing apoptosis. The presence of short
peptide motif (DKSTQTP) in BimL and BimEL mediates their binding to Dynein motor
complex via dynein light chain (DLC1); whereas, BimS doesn’t have this motif and can
potently show apoptotic activity [98]. Bmf also contains a similar motif (DKATQTLSP)
that binds to DLC2, a component of the myosin V motor complex [98].
The apoptotic activity of Bim is sequestered by binding of this protein to DLC1 of dynein
motor complex under normal condition. However, with the exposure to UV radiation, Bim
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gets detached from the DLC1 and is activated because of the phosphorylation caused by
JNK at Ser-44, Thr-56, and Ser-58 [58]. JNK mediated phosphorylation of Bim was
observed both in vivo and in vitro. Exposure to UV caused an increase in phosphorylation
of BimL in cells labeled with 32Pphosphate [58]. It was also observed that Thr-56
phosphorylation inhibits the binding of BimL to DLC1 and increases apoptotic activity
[58]. TRAIL facilitated JNK mediated phosphorylation of Bim and caused Fas-induced
liver damage. JNK and Bim deficient thymocytes were protected against TRAIL-mediated
Fas-induced damage [99].
Bim is involved in neuronal apoptosis under trophic factor withdrawal. Induction of Bim
is considered a hallmark of neuronal apoptosis. Potassium withdrawal in cerebral granule
neurons caused a five-fold increase in mRNA levels of Bim. However, with the use of
CEP-1347, the mRNA level of these BH3-only proteins were not increased to that level
even in the absence of potassium. CEP-1347 is a mixed lineage kinase inhibitor which
blocks c-Jun phosphorylation and inhibits activation under trophic factor withdrawal. The
mRNA level of Bim was upregulated by 2.8 folds. This shows that inhibiting JNK pathway
reduces the induction of Bim mRNA by ~55%. A similar trend was observed in
sympathetic neurons during nerve growth factor (NGF) deprivation [100]. However,
Putcha et al. have shown that JNK is not required for BIM induction in NGF-deprived
superior cervical ganglions. They observed that JNK signaling pathway activation is not
required for NGF-deprivation induced Bim-EL expression in sympathetic neurons. They
suggest two pathways for apoptotic cell death of NGF deprived neurons; one caused by
activation of JNK pathway and another by induction of Bim and Dp5 BH3 only proteins.
Both of them act upstream of Bax activation, so both of these pathways are required for
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NGF deprived neuronal apoptosis which acts in parallel [101]. Activation of JNK pathway
is required for, but not sufficient for, Bim-mediated death in NGF deprived neuronal
apoptosis.
Bmf, which is a related protein to Bim is also regulated by JNK, and the phosphorylation
site is the same (Thr56 and Ser58) as Bim, which is conserved in Bmf. Bmf is detached
from DLC2 when phosphorylated by JNK. JNK deficient and Bim deficient thymocytes
show a similar deficiency in apoptosis [58].
5.3.5. DP5/Hrk: Death protein 5/ harakiri (DP5, Hrk) is a BH3 only apoptotic protein
involved mostly in neuronal apoptosis [102,103]. DP5 was originally identified in rat
sympathetic neurons, during screening for genes induced after nerve growth factor (NGF)
withdrawal [104]. Hrk is a human DP5 homolog, which interacts specifically with Bcl-2
and Bcl-xL [105]. Harris et al. have shown DP5 induced neuronal apoptosis to be Bax
dependent [100]. Thus, it can be suggested that like other BH3 only protein, Hrk promotes
apoptosis either by neutralizing anti-apoptotic proteins or activating Bax.
The DP5 gene is transcriptionally regulated by JNK. This is mediated via phosphorylation
of c-Jun by JNK. It was observed that DP5/Hrk was upregulated with potassium
deprivation in cerebellar granule neurons (CGNs) [102]. DIV7 cells were cultured in
25mM or 5mM KCl containing media for different times. The increase in phospho-JNK
was observed followed by phospho-c-Jun which was further followed by an increase in
DP5 in the cells grown in 5mM KCl. Inhibition of JNK using SP600125 resulted in a
decrease in DP5 by 62%, showing that the JNK pathway is involved in transcription
regulation of DP5 under potassium deprivation [102]. Polyglutamine- repeat expansion in
the

androgen

receptor

(PolyQ-AR)

induces
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neurotoxicity

which

results

in

neurodegeneration and apoptosis in various disorders. This apoptotic cell death was found
to be mediated by Hrk, regulated by JNK via c-Jun [106].
JNK is also involved in Hrk manipulation during ceramide-mediated mitochondrial
dysfunction, as evident by the release of cytochrome c and a decrease in OMMP in human
corneal stromal fibroblasts (HCSF) [107]. JNK plays a significant role in neuronal
apoptosis by regulation of Bim/Bmf and DP5/Hrk proteins.
5.3.6. PUMA: The p53-upregulated modulator of apoptosis (PUMA), identified as a target
of p53 is a pro-apoptotic member of the Bcl-2 family of proteins [108]. It is localized to
mitochondria with a hydrophobic groove on its C-terminal domain [108,109]. PUMA binds
to anti-apoptotic proteins via the BH3 domain and activates the induction of apoptosis
[108]. PUMA is transcriptionally regulated mostly by p53 (tumor suppressor gene); there
are few observations showing regulation of PUMA by JNK.
Palmitate-induced PUMA expression was found to be JNK-dependent. In Huh-7
(hepatocarcinoma) cells treated with palmitate, an increase in JNK phosphorylation and
PUMA mRNA leading to lipoapoptosis was observed. Whereas, SP600125 caused
significant decrease in JNK phosphorylation and 70% decrease in PUMA mRNA and
protein level even with the treatment of palmitate [110]. PUMA was found to be involved
in apoptosis of cerebral granule neurons under potassium withdrawal. JNK was involved
in the induction of PUMA mRNA and increase in PUMA protein. A decrease in PUMA
protein was observed with the use of SP600125 [111].
5.3.7. Bad: Bcl-2 associated death promoter (Bad) is a pro-apoptotic protein involved in
initiating the apoptotic pathway. Once activated, it can form a heterodimer with antiapoptotic proteins (Bcl-2 and Bcl-xL) and prevent them from inhibiting apoptosis [54,112].
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Phosphorylation at different sites determines the activity of Bad. Phosphorylation of Bad
at Ser-136 or Ser-112 or both by survival factors causes the binding and sequestration of
the 14-3-3 protein, whereas phosphorylation at Ser-128 on 14-3-3 promotes the release of
Bad [113-115].
In contrast, JNK is found to be inhibiting apoptosis by phosphorylation of pro-apoptotic
protein Bad in IL-3 mediated hematopoietic cells (FL5.12) [49,116]. Unphosphorylated
Bad heterodimerizes with Bcl-xL at a non-membrane site causing inactivation of this
antiapoptotic protein. Whereas phosphorylated Bad binds to 14-3-3, causing the
sequestration of Bad in the cytosol in hematopoietic pro-B FL5.12 cells [113]. IL-3
mediated phosphorylation of Bad by JNK occurs at the Thr-201 residue. This
phosphorylation was found to reduce the association of Bad with Bcl-xL. The importance
of the Thr-201 residue of Bad in JNK mediated cell survival was shown by the generation
of a mutant, which under IL-3 withdrawal could show higher apoptotic activity compared
to wild type [49]. JNK mediated phosphorylation of Bad results in a commitment to either
death or survival under different contexts.
5.3.8. Bax and Bak: Bcl-2 associated X- protein is a cardinal member of the Bcl-2 family.
Bax regulates the critical balance between life and death [117]. Bax is predominantly a
cytosolic protein, which translocates to mitochondria by various modifications including
stress. Another reason is a conformational change in Bax with the interaction of BH3
proteins like BID and Bim, which causes its insertion into the mitochondrial membrane
[117]. Bax heterodimerizes with B-cell associated killer protein (Bak) present on
mitochondrial membrane, leading to oligomerization of Bax and Bak and initiates pore
formation in the outer mitochondrial membrane [118].
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Bax protein is sequestered in the cytoplasm by various mechanisms; one of which is
binding of Bax by 14-3-3, a cytoplasmic anchor protein [119]. Under stress, Bax
dissociates from 14-3-3 and translocates to mitochondria. JNK plays a significant role
during this translocation process, which was shown in COS-1 cells treated with anisomycin
or staurosporine. It was also shown that SP600125 or JNK binding peptide (JBP) prevented
Bax translocation. JNK phosphorylation of 14-3-3 ζ at Ser-184 and 14-3-3 σ at Ser-186
causes the dissociation of Bax. This phosphorylation was found both in vitro and in vivo in
HTC116 (colon carcinoma) cells following anisomycin treatment [120]. Another stress
shows the phosphorylation of Bax on Thr-167 by JNK and p38 kinase in response to
treatment with staurosporine, UV light, and H 2O2 in HepG2, human hepatoma cell line.
They suggest that this phosphorylation causes the conformational change in Bax which
leads to the translocation of Bax to mitochondrion [118]. JNK induced apoptosis requires
Bax and Bak, which was shown in Bax/Bak double knock out MEFs. Apoptosis was
observed with the activation of JNK in WTMEFs whereas there was no apoptosis in DKO
MEFs [121]. JNK favors apoptosis by direct modification of Bax or modification of anchor
protein ultimately resulting in translocation of Bax to mitochondria.
6. Mitochondrial permeabilization
Mitochondria are comprised of two membranes, the inner mitochondrial membrane (IMM)
and the outer mitochondrial membrane (OMM). In the space between these two membranes
(dubbed the intermembrane space), cytochrome c and various other factors are found [122].
Executor apoptotic proteins, Bax which are present in the cytosol of the normal cells
translocate to the OMM when activated. Similarly Bak is constitutively targeted to the
mitochondria after activation [55]. The activation of Bax and Bak occurs either by direct
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activators or by other proteins or non-protein factors, like mild heat, high pH and detergents
[55]. Due to the change in the structure, these proteins homo-oligomerize leading to the
formation of proteolipid pores in the OMM; OMM permeabilization occurs after a critical
number beyond the capacity of recovery has occurred. OMMP is considered the point of
no return and is the crucial event in programmed cell death [64,123]. This leads to the
release of cytochrome c, SMAC/DIABLO, endonuclease G, apoptosis-inducing factor
(AIF), adenylate kinase, Ser protease OMI, deafness dystonia protein (DDP) and OPA1,
some of which are also involved in caspase-independent cell death [65,122].
7. Mitochondrial priming and BH3 profiling
Apoptosis is a complex process regulated by several proteins; the intrinsic apoptotic
pathway is mostly regulated by Bcl-2 proteins. As mentioned before, this group of proteins
contains many members, making it difficult to analyze the complex pattern of interaction
of individual proteins. However, Letai group developed a mechanism to find the ultimate
result of this interaction. Cells are usually classified as dead or alive; they termed a third
term called ‘primed for death’ [124]. Priming determines the dependence of cells on antiapoptotic proteins for survival [125]. In response to death signaling received, these ‘primed
cells’ have pro-apoptotic proteins sequestered by anti-apoptotic Bcl-2 proteins.
Mitochondrial priming is used to reveal the degree of proximity to death. It correlates with
the clinical response to chemotherapy. It can be used to characterize patients’ tissue into
chemo-resistant and chemo-sensitive [126].
The Letai group developed a technique to measure priming called BH3-profiling. BH3profiling is proposed to measure mitochondrial priming in patients to guide a personalized
selection of the best chemotherapeutic regimen for a patient. BH3-profiling not only
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determines if the tumor cells are primed for death, but it can also determine which antiapoptotic proteins promote the survival of resistant samples [124,127]. Letai group have
developed different ways of BH3-profiling. In this technique, mitochondria are isolated
and treated with a panel of BH3-peptides and as a measure of the formation of OMMP
release of cytochrome c or change in MMP is assessed. A fluorescent-associated cell
sorting (FACS) for the measurement of MMP or cytochrome c can be utilized. However,
a plate-based assay is commonly used for homogeneous cell population whereas FACS can
be used in heterogeneous cell population [125].
Using B-cell lymphoma as a model, the Letai group classified cancer cell into three classes.
Class A has suppression of pro-apoptotic activator BH3 proteins, Class B has lost Bax and
Bak, effector Bcl-2 protein and Class C has high expression of anti-apoptotic Bcl-2 protein.
Further class C cells which were sensitive to ABT-737, a BH3-mimetics, the anti-apoptotic
protein particularly responsible for survival was identified [127]. This method can be used
to find the dependency of on anti-apoptotic protein for survival. For example, a tumor it
could be dependent on either Bcl-2 or Mcl-1 and Bcl-2 antagonists ABT-263 or ABT-199
could be used in that patient [125]. This classification helps in determining the
chemotherapeutic drug that will work best in the patient.
8. SH3BP5 (Sab)
Sab (also called SH3 binding protein 5 or SH3BP5) was first identified as a novel molecule
binding to SH3-domain of Bruton’s tyrosine kinase (Btk) using protein interaction cloning
method [128]. Sab is a scaffold protein present on the OMM [129]. Sab has three
interaction motifs; kinase interaction motifs (KIM-1 and KIM-2) and SH3-binding motif
[130,131]. A yeast-two hybrid screening method showed that C-terminus of Sab binds to
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JNK [130]. C-terminus also has potential phosphorylation sites that can be assigned to
MAPKs. The C-terminus is present on the outside of the mitochondria facing cytoplasm
while N-terminal lies in between inner and outer membrane coil-like structure similar to
myosin heavy chain [131]. Sab has been shown to facilitate pro-apoptotic signaling events
in response to cytotoxic stress. One of the major known interacting partners of Sab is JNK;
the interaction between these two have been shown to be involved in mitochondrial
dysfunction and cell death in few studies. However, other mechanisms regulating Sab is
not known yet.
8.1. Sab and JNK interaction
Sustained activation of JNK leads to its translocation to mitochondria [48,129]. The
interaction between JNK and Sab was found to ‘prime the mitochondria’ for JNK signaling
in the presence of 25m of anisomycin for 30 minutes. It was observed that interaction of
Sab with JNK results in initiation of the apoptotic pathway which occurs via KIM-1 motif.
While inhibition of Mito-JNK signaling which was mediated by Sab, no mitochondrial
dysfunction was observed [48]. It was shown that JNK-Sab interaction leads to
phosphorylation of the anti-apoptotic protein Bcl-2, which leads to its emigration from
mitochondria and favors the accumulation of pro-apoptotic BH3 only proteins [48]. The
interaction between Sab and JNK leads to inhibition of respiration, increased reactive
oxygen species (ROS) which further endures JNK activation and causes cell death
[48,52,132,133]. JNK-Sab interaction leading to cell death has been observed in different
disease models, which are inhibited by inhibiting JNK-Sab interaction or silencing of Sab.
Acetaminophen or tumor-necrosis factor-induced liver injury requires JNK-Sab interaction
[129]. In addition to this, the JNK-Sab nexus is involved in palmitic acid-induced
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hepatocyte lipotoxicity, tunicamycin ER-stress induced apoptosis [134,135] This
highlights the importance of the JNK interaction with scaffold protein Sab for causing
mitochondria-mediated cell death.
The potential for the levels of Sab on the OMM to indicate the robustness of apoptotic
induction was first illustrated by sub-chronic administration of LY294002 in HeLa cells
[52]. Increasing Sab-levels by subchronic exposure to LY294002 could enhance the
efficacy of cisplatin and paclitaxel in HeLa cells. While silencing of Sab or inhibition of
JNK-Sab interaction did not increase the efficacy of these agents but rather promoted
resistance [52]. We suggest that this technique of increasing Mito-JNK signaling by
increasing Sab could be used to restore or enhance apoptosis in drug-resistant cancer cells.
9. Conclusion
Few investigations have examined the involvement of Mito-JNK in chemotherapeuticinduced death in OC cells; even though, a broad inhibition of JNK reveals a contribution
to cisplatin- and paclitaxel-mediated apoptosis. There is even less information regarding
the role of Sab in chemotherapeutic responses. The Chambers and Kaplowitz groups’
collective research demonstrates the importance of Sab in mediating toxic JNK signaling
events under different stress conditions. Increasing Sab concentration increases Mito-JNK
signaling and consequently the potential to induce apoptosis through the manipulation of
Bcl-2 proteins; however, the molecular mechanisms relating chemotherapeutic efficacy
and Sab concentration have not been explored in gynecological cancers. This endeavor will
be the subject of my dissertation research.
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CHAPTER 2
HYPOTHESIS AND RATIONALE
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1. Problem Statement
Gynecological cancer mortality can be attributed to the presence of recurrent, highly
metastatic, and resistant disease [1]. Unfortunately, the molecular mechanisms responsible
for the resistance to conventional therapies are not thoroughly defined. Because of this
knowledge gap, treatment-resistant gynecological cancers are responsible for diminished
survival in late-stage ovarian and uterine cancer patients [2]. Thus, until the mechanisms
driving therapeutic resistance are defined, effective therapies for advanced gynecological
cancers will likely remain elusive. Therefore, it is the goal of this research to identify and
characterize molecular events responsible for therapeutic resistance in gynecological
cancers. By elucidating these events, one anticipates that new treatments targeting these
specific molecular alterations can be developed to reestablish cell death induction in many
difficult to treat tumors.
2. Hypothesis and Rationale
The inability of tumor cells to induce cell death mechanisms is a hallmark of cancer [3]. A
recent study demonstrated that treatment with a chemosensitizer (LY294002) altered cell
death signaling on the mitochondrial surface, the site for induction of apoptosis [4]. Subchronic, low-dose treatment with LY294002 increased the concentration of the outer
mitochondrial scaffold protein Sab. Because the concentration of scaffold proteins dictate
the biological outcomes of signaling pathways at discrete subcellular locales [5, 6], one
could propose that increased Sab levels on mitochondria would correspond to enhanced cJun N-terminal Kinase (JNK) signaling on the organelle. Indeed, chemosensitization did
increase the drug-induced translocation of JNK to mitochondria and lowered the threshold
for apoptosis in a Sab-dependent manner [4]. Based on this study and other relevant
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literature (See Chapter 1), the over-arching hypothesis of this project is that decreased Sab
expression in gynecological cancers is in part responsible for chemotherapeutic resistance
in late-stage disease. Furthermore, therapeutic strategies aimed at elevating the local
concentrations of Sab on mitochondria may represent useful approaches to restore cell
death induction in treatment-resistant gynecological tumors. The rationale for this research
is once approaches are found to restore apoptotic pathways in gynecological tumors
efficacious treatments can eliminate the disease resulting in increased patient survival and
improve quality of life.
3. Project Aims
To investigate the hypothesis, and accomplish the research goal, the approach for this
project is to understand the role of mitochondrial signaling in drug resistance for
gynecological cancers and develop an approach to restore mitochondrial JNK signaling
and induction of apoptosis in tumor cells. For this purpose, the following specific aims are
proposed.
a. Identify the role of Sab in mitochondrial JNK signaling and mitochondrial priming
in gynecological cancers.
b. Identify and characterize compounds that increase Sab concentrations in treatmentresistant gynecological cancer cells.

4. Chapter Abstracts
The project has resulted in three submitted manuscripts, which will comprise Chapters 3,
4, and 5 of the dissertation. To preview these chapters, the abstracts from these
manuscripts/chapters appear below:
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Chapter 3 - Sab Concentrations Indicate Chemotherapeutic Susceptibility in
Ovarian Cancer Cell Lines
The occurrence of chemotherapy-resistant tumors makes ovarian cancer (OC) the most
lethal gynecological malignancy. While many factors may contribute to chemoresistance
in OC, the mechanisms responsible for regulating tumor vulnerability are under
investigation. Our analysis of gene expression data from OC studies revealed that Sab, a
mitochondrial outer membrane (OMM) scaffold protein, was down-regulated in OC
patients. Our previous studies demonstrate that Sab-mediated signaling on the OMM
induces cell death suggesting that this apoptotic pathway may be diminished in OC. In the
current study, we examined Sab expression in a panel of OC cell lines and found that the
magnitude of Sab expression correlated to chemo-responsiveness; wherein, OC cells with
high Sab concentrations were vulnerable to chemotherapy, while cells with low Sab levels
were chemoresistant. The Sab levels were reflected by a complementary amount of the cJun N-terminal kinase (JNK) on the OMM in response to cytotoxic stress. Dynamic BH3
profiling and examination of Bcl-2 and BH3-only protein concentrations revealed that cells
with high Sab expression were primed for apoptosis, as determined by the decrease in prosurvival Bcl-2 proteins and an increase in pro-apoptotic BH3-only proteins on
mitochondria. Furthermore, over-expression of Sab in chemoresistant cells enhanced
apoptotic priming and restored cellular vulnerability to a combination treatment of cisplatin
and paclitaxel. Contrariwise, inhibiting Sab-mediated signaling or silencing Sab expression
in a chemosensitive cell line resulted in decreased apoptotic priming and increased
resistance to cisplatin/paclitaxel treatment. We propose that Sab may be a prognostic
biomarker to discern personalized treatments for OC patients.
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Chapter 4 – Sab Concentrations Indicate Chemotherapeutic Susceptibility in
Uterine Cancer Cell Lines
Metastatic uterine cancer (UC) has a 5-year survival less than 8%. This mortality is
associated with treatment resistance in metastatic UC cells. There is an urgent need to
identify the mechanisms contributing to resistance in UC patients with metastatic disease
to improve the patient survival. Mitochondria control cell death responses, yet cancer cells
can develop mechanisms to avoid apoptosis and evade therapeutic approaches. We propose
communication between the cell and mitochondria becomes altered during metastasis, and
metastatic UC cells have mitochondria that can no longer process cell death signals. To
address if mitochondrial-cell communication was altered during metastasis, we compared
a human cell line derived from a primary site tumor (SK-UT-1) and another isolated from
a metastatic site (AN-3-Ca). Analysis of the signaling proteins on the surface of the
mitochondria in these two cell lines revealed that a scaffold protein, Sab, was downregulated in metastatic AN-3-Ca cells compared to SK-UT-1. Our previous research
demonstrated that elevated levels of Sab induced mitochondrial dysfunction and apoptosis,
ultimately enhancing chemo-responsiveness in gynecological tumors. We examined the
apoptotic potential of SK-UT-1 and AN-3-Ca cells by measuring the levels of pro-survival
Bcl-2 proteins and pro-death BH-3 only proteins. Our results indicate that metastatic AN3-Ca cells had considerably higher levels of Bcl-2 proteins, while SK-UT-1 cells had
higher levels of BH-3 only proteins. We found that AN-3-Ca cells were more resistant to
taxane and platinum treatment than SK-UT-1 cells. To determine if diminished Sabmediated signaling played a role chemo-resistance, we ectopically expressed Sab in AN3-Ca cells. Elevating Sab levels in AN-3-Ca cells rescued chemo-responsiveness by
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decreasing Bcl-2 protein levels and increasing BH-3 only protein concentrations. We
surmise that Sab-mediated signaling plays a critical role in treatment responsiveness in UC
and that inhibiting Sab expression is a critical event in metastasis and chemo-resistance.

Chapter 5 - A high-throughput Assay to Screen for Compounds Elevating Sab
Concentrations in Chemoresistant Human Ovarian Cancer Cells.
Ovarian cancer (OC) is the most lethal gynecological malignancy. OC mortality is
associated with the high rate of recurrence, which stands at approximately 80%.
Recurrence is typified by the presence of treatment-resistant cells; consequently,
conventional therapies, including chemotherapy, are often ineffective. Therefore, it is
imperative to find novel therapeutic options to eliminate treatment-resistant OC cells. We
propose that targeting mitochondrial-cell communication in resistant OC cells will increase
their susceptibility to established chemotherapies. Previous studies from our lab
demonstrate that increasing the concentration of the outer mitochondrial scaffold protein
Sab sensitizes OC cells to paclitaxel by inducing apoptotic priming. These studies suggest
that increasing Sab levels in OC will induce a pre-apoptotic state and sensitize the tumor
cells to conventional chemotherapies, thus rendering resistant OC cells sensitive. We have
developed a high-throughput assay, an in-cell western (ICW), to detect changes in Sab
protein concentrations following chemical exposures. The ICW approach was developed
in HEK-293 cells and validated using Sab silencing and overexpression. A trail screen of
known compounds found that mitochondrial toxins were the most potent enhancers of Sab
levels, while antioxidants were the greatest suppressors of Sab levels. The ICW assay was
re-optimized in SK-OV-3 cells (z- score of 0.81), a chemoresistant cell line. The Sab ICW
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was co-stained with the TO-PRO-3 DNA stain for normalization and as an index of
viability. We screened a scaffold-ranking and positional-scanning library (provided by the
Torrey Pines Institute for Molecular Studies) to identify novel compounds that increase
Sab expression in OC cells. Fifty (50) chemical scaffolds were screened for SK-OV-3 cells.
Scaffolds selected for further testing increased Sab expression greater than 30% and
demonstrated minimal toxicity in SK-OV-3 cells. Using this method we have identified six
candidate scaffolds. Individual compounds derived from this scaffold are currently being
evaluated to identify the best compounds for OC studies. We predict that this approach will
identify novel drugs that will improve OC treatment and mortality.
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SUSCEPTIBILITY IN OVARIAN CANCER CELL LINES.
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1. Introduction

Ovarian cancer (OC) is the most lethal gynecological malignancy [1]. While the overall 5year survival for OC is approximately 45%, 60% of OC patients suffer from the metastatic
disease, which has a survival rate of nearly 28%; whereas, locally detected OC cases have
a 92% survival rate [2].

The high mortality associated with OC is attributed to a

combination of poor detection and an extremely high recurrence rate (~80%) [3]. Recurrent
OC is typified by the presence of treatment-resistant tumor cells [4]. Specifically, OC
patients are often characterized by their relative responsiveness to platinum-based drugs,
which are commonly used chemotherapy agents for OC [4, 5]. Patients are classified as
platinum-sensitive (recurrence after six months), platinum-resistant (recurrence in less than
six months) or platinum-refractory (recurrence during or upon completion of
chemotherapy) [6], and this patient stratification is used, in part, to determine treatment
options. In fact, the front-line treatment of paclitaxel and a platinum agent, such as
cisplatin, only provides a modest improvement in survival among OC patients [7, 8]. Thus,
the molecular mechanisms driving chemoresistance need to be defined and targeted to
enhance treatment responsiveness in OC patients. To date, many factors have been
implicated and targeted in platinum-resistant/refractory OC to improve therapeutic
efficacy. These include angiogenesis [9, 10], perturbations in cellular signal transduction
[11-15], DNA maintenance and repair machinery [7, 16], folate metabolism [17, 18], and
mitochondrial physiology [19-21].

Recent research has demonstrated that changes in the apoptotic potential (ability to induce
cell death) is altered in advanced OC patients [22, 23]. Specifically, a decrease in the
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relative abundance of pro-apoptotic BH3-only proteins is linked to chemoresistance in OC.
BH3-only proteins (Bad, Bid, Bik, Bim, Noxa, and Puma) are members of the Bcl-2
superfamily of proteins and facilitate apoptosis by sequestering pro-survival Bcl-2 proteins
or enhancing mitochondrial outer membrane permeabilization (OMMP) by catalyzing the
assembly of Bax-Bak pores [24, 25]. Because of the association among BH3-only proteins,
apoptosis, and chemo-responsiveness, BH3 profiling, a reproducible, high-throughput
assessment of BH3-only protein levels, has been proposed to be an index for chemoresponsiveness in solid tumors, including OC tumors [26-28]. Recent BH3 profiling efforts
have found that indeed OC cells with high levels of BH3-only proteins were sensitive to
chemotherapy [22, 23]. Moreover, increasing BH3-only protein concentrations, emulating
BH3-only functions with chemical mimetics (ABT-737), and inhibiting pro-survival Bcl2 proteins have been found to enhance chemotherapeutic efficacy in resistant OC cells [23,
24, 29]. However, the precise molecular mechanisms controlling the relative levels of BH3only proteins on mitochondria in OC are currently being investigated and may represent
new therapeutic and prognostic targets.

The outer mitochondrial membrane (OMM) is the interface between mitochondria and the
rest of the cell. The OMM is not only the primary site of signal integration for mitochondria
[30], but the OMM is also the location of Bcl-2 superfamily proteins, including several
BH3-only proteins [31, 32]. Signaling complexes on the OMM may influence many
aspects of mitochondrial physiology, including the recruitment, function, and retention of
BH3-only proteins. Previously, we found that the OMM scaffold protein Sab organized
pro-apoptotic signaling cascades in response to cytotoxic stress [33-35]. Specifically, the
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c-Jun N-terminal kinase (JNK) translocated to the mitochondria and interacted with Sab in
human cervical cancer (HeLa) cells treated with anisomycin [34]. Selective inhibition of
the JNK-Sab interaction using a small, cell-permeable peptide (Tat-SabKIM1) prevented
JNK-induced apoptotic events such as phosphorylation and emigration of Bcl-2 from the
OMM [33]. Recently, we reported that sub-chronic treatment of HeLa cells with a chemosensitizer, LY294002, increased Sab expression and chemosensitivity towards cisplatin
and paclitaxel, two drugs commonly used in combination to treat OC [35]. In general,
enhanced Sab-mediated signaling may increase the sensitivity of cells to toxic stress [36],
including OC tumors. However, we have yet to determine the precise molecular
mechanisms by which Sab-mediated signaling may reduce chemoresistance.

In our current study, we examined the role of Sab-mediated signaling in OC chemoresponsiveness. Analysis of gene expression data from six, independent OC patient studies
shows that Sab expression is reduced more than five-fold on average across 970 OC
samples when compared to normal tissue. Profiling four commercially available OC cell
lines revealed that cells with high Sab expression are sensitive to common chemotherapy
agents and that Sab levels reflect the concentrations of BH3-only proteins on mitochondria.
Additionally, over-expression of Sab in the chemoresistant SK-OV-3 cell line increased
BH3-only protein levels and chemosensitivity to cisplatin and paclitaxel treatment.
Conversely, inhibition of Sab-mediated signaling in a chemosensitive cell line, PA-1, was
sufficient to enhance chemoresistance to paclitaxel and cisplatin. Our studies demonstrate
that manipulation of OMM signaling, such as increasing Sab-mediated signaling events,
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may be a useful strategy to determine viable, personalized treatment options for OC
patients.

2. Experimental procedures

Materials: Cell lines were purchased from American Type Culture Collection (ATCC,
Manassas, VA). Human Ovarian Epithelium Cells were obtained from ScienCell Research
Laboratories (Carlsbad, CA). Chemotherapeutic agents ABT-737, carboplatin, cisplatin,
docetaxel, doxorubicin, etoposide, and paclitaxel were purchased from Sigma-Aldrich (St.
Louis, MO). Antibodies were purchased from vendors as listed below. General laboratory
supplies were purchased from Fisher Scientific (Pittsburgh, PA).

Gene Expression Analysis: Secondary data analysis was performed to determine the
relative levels of Sab expression in normal and OC tissue samples. The expression of Sab
(SH3-binding protein 5; SH3BP5) was examined using the Oncomine database
(http://www.oncomine.org) in March 2017 [37]. By querying six datasets available for OC
that included Sab as part of past studies [38-43], we compared experimental data for normal
tissue and OC samples. The data were compiled from across six independent studies, which
contained a total of 41 normal tissue samples and 970 OC samples (1,011 samples in total).
The data were presented as medians with error bars with limits of the 90 th and 10th
percentiles. All of the OC samples were from surgically removed primary site tumors
(summarized in Table 1).

Cell Culture: OC cell lines CaOV-3 (HTB-75), PA-1 (CRL-1572), SW-626 (HTB-78), and
SK-OV-3 (HTB-77) cells were cultured according to the suppliers instructions in
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Dulbecco's Minimal Essential Medium (DMEM), Eagle’s Minimal Essential Medium
(EMEM), Lebovitz L15 medium, and McCoy’s 5a medium, respectively. Each medium
was supplemented with 10% fetal bovine serum (FBS), 1,000 U/mL penicillin, 100mg/mL
streptomycin, and 5g/mL plasmocin. For experiments, cells between passages 3 and 20
were used. To account for media-induced effects, cells were also adapted to DMEM and
analyzed as described below. Human ovarian epithelium cells were cultured under normal
cell culture conditions on poly-L-lysine-coated plates according to manufacturer’s
instructions using Ovarian Epithelial Cell Medium (ScienCell Research Laboratories) for
no more than five passages.
Immunoblotting: To isolate proteins from cells for analysis, cells were plated at 2.5x105
cells/well in six-well plates and 60-mm dishes. Following treatment, cells were lysed, and
proteins were harvested as previously described. Briefly, cells were washed twice in
phosphate buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM
KH2PO4) and lysed in radioimmunoprecipitation assay buffer (RIPA; 50mM Tris-HCl, pH
8.0, 150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS) supplemented with
1mM phenylmethanesulfonyl fluoride (PMSF) and Halt Protease and Phosphatase
Inhibitor Cocktails (Thermo Scientific). Cells were incubated while gently rocking at 4°C
for five minutes, and then transferred to a sterile microcentrifuge tube. After two minutes
on ice, cell disruption was completed using sonication. The lysate was cleared by
centrifuging at 14,000 × g for 15 minutes. Supernatant protein concentrations were
measured using the Pierce BCA Assay kit. Proteins (25g) were resolved by SDS-PAGE
and transferred onto low-fluorescence PVDF membranes. Membranes were placed in
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blocking buffer comprised of PBS with 5% bovine serum albumin (BSA) and incubated
for one hour at room temperature. The membranes were incubated in PBS containing 0.1%
Tween 20 (PBST) and 5% BSA in the presence of primary antibodies overnight (4 oC) while
gently rocking. Primary antibodies specific for Sab (Novus Biologicals, H00009467M01), Phospho-JNK (Thr183/Tyr185, Cell Signaling Technology (CST), 4668), JNK (Cell
Signaling Technology, 9252), Phospho-c-Jun (Ser73, CST, 3270), c-Jun (CST, 9165),
Phospho-Bcl-2 (Ser70) (CST, 2827), Bcl-2 (CST, 2870), Bcl-xL (CST, 2764), Mcl-1 (CST,
5453), Bad (CST, 9239), Bik (CST, 4592), Bim (CST, 2933), Bid (CST, 2002), PUMA
(CST, 12450), Bax (CST, 5023), Bak (CST, 12105)Actin (CST, 4970), α-tubulin (CST,
2144), COX-IV (CST, 4850), GAPDH (CST, 5174), Calnexin (CST, 2679), Histone H3
(CST, 4499), TOM20 (Abcam, ab115746), TIMM23 (Abcam, ab116329), and PEX19
(Abcam, ab137072) were used at dilutions of 1:1000. Membranes were washed three times
for five minutes in PBST and were incubated with secondary antibodies in the appropriate
blocking buffer at a ratio of 1:20,000 for one hour at RT gently rocking. The following
secondary antibodies were used in the experiments below: IRDye 680RD goat anti-rabbit
(926-32211) and IRDye 800CW goat anti-mouse (926-68070) (Licor Biosciences).
Membranes were again washed three times for five minutes in PBST. Membranes were
analyzed using fluorescence detection using the Odyssey CLx near infrared scanner (Licor
Biosciences). The corresponding bands on the immunoblots were quantified and
normalized using the Image Studio 2.0 software (Licor Biosciences). The fluorescence of
specific bands of interest was divided by the fluorescence of the loading control band to
equilibrate signal strength and loading. The resulting signal was then normalized by
dividing the signals from treated samples by untreated controls for each experiment.
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Cell-based IC50s of Chemotherapeutic Agents: To determine the relative chemo-sensitivity
of the OC cell lines, cells were treated with increasing concentrations (generally 0-100M)
of drugs approved for the treatment of OC. Cells were plated at 1.5x10 4 cells per well in
black-walled, clear bottom plates (Perkin Elmer) and grown overnight. The cells were then
treated with chemotherapeutic agents for 48 hours. The cells were washed three times with
PBS and fixed in 4% paraformaldehyde/PBS. The cells were then stained with 5M TOPRO-3 for 45 minutes at RT [35, 36]. The cells were then washed three times in Hank’s
Buffered Saline Solution (HBSS). The plate was imaged using the Odyssey CLx scanner
(Licor Biosciences) and analyzed using the Image Studio 2.0 software (Licor Biosciences).
The IC50s were then calculated using the GraphPad Prism7© software.

Mitochondrial Isolation: To determine the relative abundance of proteins located on or
within mitochondria, we isolated mitochondria as described in our previous work [33, 36].
Mitochondrial preparations with greater than 75% purity were used for our studies.
Mitochondria purity was determined by immunoblotting for proteins from other subcellular
compartments. For protein analyses, a total of 50g protein was loaded for each
mitochondrial sample.

JNK Activity Assay: We have previously used a luciferase-based kinase activity assay
(Promega’s Kinase-Glo Assay) to determine cellular JNK activity [33, 63]. In this study,
mitochondria were isolated from each cell type, and the organelles were lysed using a
native lysis buffer (25mM Tris-HCl [pH 7.5], 150mM NaCl, 1mM EGTA, 1mM EDTA,
1% TritonX-100) supplemented with protease and phosphatase inhibitors (Halt Cocktails
– Thermo Fisher Scientific). Next, the mitochondrial lysate was placed in JNK activity
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buffer (25mM HEPES, pH 7.4, 10mM MgCl2, 2mM dithiothreitol (DTT), 1mg/mL BSA,
and 1µM ATP). Then, 1µM of peptide substrate: either c-Jun (1-79) peptide, recombinant
Sab polypeptide (335-435), or mutant Sab polypeptide (335-435) with mutated JNK
binding sites to prevent kinase docking (Sab KIM1/2L-A(335-435)) was added. Sab peptides
were expressed and purified as previously described [33, 64]. As a control for JNK activity,
specific lysates were pretreated fifteen minutes with 10M SR-3306 (Tocris) to inhibit
JNK. The assays were incubated for one hour at 30oC, and the reaction was stopped by the
addition of 50mM EDTA. The reaction was combined with an equivalent volume of
Kinase-Glo reagent and incubated at room temperature for ten minutes. Luminescence was
measured on the BioTek Synergy H1 microplate reader with 500ms integration. ATP
concentrations were determined by interpolating results onto an ATP standard curve
acquired during each kinase reaction replicate. The data are reported as mean relative
luminescence and normalized to protein concentration (mg) with error bars representing
one standard deviation of the mean.

Apoptotic Priming Assay: To examine the potential for OC cell lines to induce apoptosis,
we employed dynamic BH3-profiling, a high-throughput technique to predict the
responsiveness of tumors to therapy [23, 26, 29, 65]. First, 2.0x104 cells were used for the
analysis of each cell line. The cells were trypsinized and dispersed into single cell
suspensions, as determined by microscopy, in Trehalose Experiment Buffer (T-EB,
300mM Trehalose, 10mM HEPES-KOH (pH 7.7), 80mM KCl, 1mM EGTA, 1mM EDTA,
0.1% BSA, and 5mM succinate) at four times the final density. Bim BH3-peptide
(MRPEIWIAQELRRIGDEFNA) was prepared as ten distinct concentrations over a three

63

log margin ranging in concentrations from 0.01mM to 100mM to determine the optimal
conditions of the assay. A concentration of 500nM was determined to be the optimal
concentration of Bim BH3 assays in HeLa cells and later used for our profiling of OC cell
lines. Next, 15L of Bim BH3-peptide was placed in a black 384-well plate (Nunc
262260). One volume (7.5L) of the cell suspension was combined with one volume
(7.5L) of JC-1/Digitonin Mastermix (4mM JC-1, 40g/mL oligomycin, 20mM mercaptoethanol, and 0.02% digitonin in T-EB). The cells were permeabilized for 10
minutes at room temperature. The 15L of cell/dye solution was then added to the Bim
BH3-peptide in the respective well of the 384-well plate. When completed, the plate was
placed inside a BioTek Synergy H1 plate reader and shaken for 15 seconds. The
fluorescence was then monitored at 590nM (excitation 545nM; with 20nM bandwidths)
every five minutes for 120 minutes. As a positive control for complete depolarization, cells
were treated with 3M Carbonyl-cyanide-p-trifluoro-methoxy-phenylhydrazone (FCCP)
and 250nM valinomycin. For each biological replicate, experimental conditions were
performed in replicates of five for each cell line; experiments with a standard deviation of
less than 10% were used for our analysis. The percent priming (% priming) was found by
subtracting the mean maximum depolarization (FCCP/Valinomycin) from the mean
depolarization from Bim BH3-peptide treatment across replicates. The change in priming
(% priming) refers to the difference in priming between non-treated, and Bim BH3peptide-treated cells [22].

Mitochondrial outer membrane permeabilization: To evaluate the integrity of the OMM,
we chose to quantify the amount of cytosolic cytochrome c [36]. Extra-mitochondrial
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cytochrome c concentrations were assessed using immunoblotting of subcellular fractions
(mitochondria and S100 (cytosol)). Briefly, 5x107 cells were grown in two 150-mm dishes.
The cells were resuspended in 800L of ice-cold homogenization buffer (250 mM sucrose,
20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
pH 7.4 and Halt protease inhibitor cocktail). The cells were homogenized and centrifuged
(750xg, 10 minutes, 4oC) to remove nuclei and intact cells. The supernatant was
centrifuged (10,000xg, 10 minutes, 4oC). The resulting supernatant was transferred to a
new tube, and the pellet (or mitochondria-containing fraction) was resuspended in
homogenization buffer. The supernatant was centrifuged at 100,00xg (4 oC) for 60 minutes
yielding the cytosolic fraction. Finally, 50g of protein was resolved by SDS-PAGE, and
cytochrome c was detected by immunoblotting as described above.

Manipulation of Sab-mediated signaling: We transiently transfected SK-OV-3 (a low Sab
expressing OC line) with plasmids designed to express Sab (pLOC:Sab), red fluorescent
protein (RFP; pLOC:RFP), or a Sab mutant lacking MAPK binding motifs (Sab KIM-2L/A;
pLOC: SabKIM-2L/A) [35, 36] to evaluate the impact of increased Sab levels. Plasmid DNA
and FugeneHD (Promega) were combined in Optimem (Invitrogen) at a ratio of 1:3 and
incubated for 15 minutes at RT before addition to culture. Eight hours after the addition of
the transfection complex to media, the media was exchanged. Protein levels were assessed
at 72 hours post-transfection. For drug-related studies, chemotherapeutic agents were
added at 48 hours post-transfection, and cell viability was measured at 96 hours posttransfection (48 hours after drug).

To reduce Sab-mediated signaling in a high Sab-expressing OC cell line (PA-1), we used
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peptide-based inhibition of protein-protein interactions on Sab as described in our prior
studies. Cells were treated with up to 10M of Tat-SabKIM1 (a cell-permeable, inhibitory
peptide) [33], scrambled control peptide (Tat-Scramble), or a variant of Tat-SabKIM1
lacking the intact MAPK binding site (Tat-SabKIM1L/A). Cells were plated as described
above and then treated with peptide for thirty minutes before drug treatment.

To decrease Sab expression, PA-1 cells were transiently transfected with pLKO.1 plasmids
containing shRNAs either a luciferase-specific shRNA (control) or a shRNA for Sab that
demonstrated over 85% silencing in 72 hours (Supplemental Figure 3). Ectopic expression
of a shRNA-resistant form of Sab (previously described in [35]) was used to rescue Sab
levels in PA-1 cells silencing Sab. Briefly, 1.5x104 cells were plated in a 96-well plate, or
1.5x105 cells were plated a day before transfection in 35-mm dishes for experiments.
Plasmids were mixed with FugeneHD (Promega) at a 3:1 ratio per manufacturer’s
recommendations and added to cells for up to 72 hours. Protein levels were determined by
immunoblotting as described above.

Cell Viability: To determine the extent of cell death, we utilized two methods: 1) AnnexinV with propidium iodide (PI) analyzed by fluorescent microscopy and 2) Caspase 3/7
fluorescent activity assay [66-68]. For the Annexin-V/PI assays (Cayman Chemical),
1.5x104 cells were plated in a black-walled optically-clear bottom 96-well plate (Nunc),
and the cells were treated with the chemotherapy agents as described above. The plate was
centrifuged at 400xg for five minutes, and the media was removed. The cells were then
placed in 100L of Binding Buffer; the plate was centrifuged again (400xg, 5 minutes) and
the buffer was removed. The cells were then incubated in 50mL of Annexin-FITC/PI
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solution for ten minutes at room temperature, and the solution was removed following
centrifugation (400xg, 5 minutes). The cells were placed in 100L of HBSS, and the cells
were imaged by fluorescent microscopy using the Applied Precision DeltaVision Elite
Imaging System. Images were analyzed by counting cells stained only with unstained,
Annexin-V-FITC stained (early apoptosis), and double labeled, Annexin-V/PI stained cells
(late apoptosis). As a positive control, cells were treated with 1M staurosporine (STS) to
induce significant cell death at 24 hours. Images were assembled using Adobe Photoshop.
For the cell-based caspase 3/7 activity assay, cells were grown in a clear 96-well plate as
described for the Annexin-V/PI assay. The plate was centrifuged (400xg) for five minutes,
and the supernatant was removed. The cells were placed in 150L of PBS and centrifuged
(400xg for 5 minutes). After removing the buffer, the cells were placed in 100L of PBS
supplemented with 1% TritonX-100 to lyse the cells. After thirty minutes of incubation on
a room temperature orbital shaker, the plate was centrifuged at 800xg for ten minutes, and
90L of the cleared lysate was transferred to a black 96-well plate. Next, either 10L of
PBS or 10L of a caspase inhibitor (Ac-DEVD-CHO; 10M) was added to the lysate.
Then, 100L of caspase substrate Ac-DEVD-AMC (100M) in PBS supplemented with
20mM DTT was added to the well. The assay was incubated at 37oC for thirty minutes,
and fluorescence was measured (excitation: 488nm; emission: 535nm) using the BioTek
Synergy H1 plate reader. Each assay was performed in triplicate for each condition for a
minimum of four biological replicates. Data are presented as mean relative fluorescent
units.
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Biological Replicates and Statistics: A minimum of five biological replicates were used for
cell-based studies, while a minimum of six experimental replicates was evaluated for
biochemical, fluorescence, and other measurements. To determine statistical significance,
the Mann-Whitney test was employed for significance between treatments. Statistical
significance is indicated by an asterisk in figures in which the p-value is less than 0.05.
Data are displayed as means with error bars representing plus and minus one standard
deviation of the mean.

3. Results

3.1. Sab expression is reduced in OC. Our previous study in HeLa cells demonstrated
that increasing the concentration of Sab on the OMM enhanced the sensitivity towards
cisplatin and paclitaxel [35]. Because OC is typified by the presence of tumor cells resistant
to platinum drugs, such as cisplatin, we wanted to determine if Sab expression may be
altered in OC patients. To determine if Sab expression was changed in OC, we queried the
Oncomine database [37] for Sab expression in OC samples and normal ovarian tissue.
Examination of six independent studies (Table 1) found that Sab levels were reduced on
average ~5.5-fold (2.19-fold in log2 scale) in primary site OC tumors when compared to
normal tissue [38-43]. We plotted the medians, 90th percentile values, and 10th percentile
values for each study in Figure 1. This analysis of 970 OC samples had a p-value less than
0.001 indicating a difference in Sab expression, at least at the mRNA level, between the
normal tissue and OC tumors (Table 3.1)
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Table 3.1: Summary of Ovarian Cancer Expression Studies and Observed Changes in Sab Expression.

STUDY

ABID

TOTAL
SAMPLES

16

CANCER
SAMPLES

NORMAL
SAMPLES

OVARIAN
CANCER
TYPES**

NORMAL
TISSUE

GENES
ANALYZED

HUMAN
GENOME
ARRAY(S)

LOG2
FOLD
CHANGE

AVG.
FOLD
CHANGE

P

REF.

12

4

Serous
Carcinoma

Ovary

8,603

U95AAv2

-2.331

-5.032

0.003

(38)

Ovarian
Carcinoma

Ovarian
Surface
Epitheliu
m

12,624

U133A

-3.776

-13.699

7.18
E-9

(39)

Ovary

12,624

U133A

-1.446

-2.725

1.43
E-5

(40)

Ovarian
Surface
Epitheliu
m

17,572

U95AAv2
U95B
U95C
U95D
U95E

-1.285

-2.437

0.067

(41)

Ovary

12,624

U113A

-1.684

-3.213

1.17
E-7

(42)

Peritoneu
m

16,724

Agilent
1A Oligo
v2

-2.619

-6.143

2.10
E-9

(43)

-2.190

-5.542

BONOME

195

185

10

HENDRIX

103

99

4

LU

50

45

5

TCGA

594

586

8

YOSHIHARA

53

43

10

TOTALS/MEANS*

1,011

970

41

Multiple**

Multiple**

Ovarian
Serous
Cystadenocar
cinoma
Ovarian
Serous
Adenocarcino
ma

The data presented in the table was obtained from the Oncomine repository and statistically reexamined for Sab (SH3BP5)
expression. *The number of samples from each study were added to arrive at the total numbers used for our evaluation. The
mean fold changes were generated by averaging the fold changes from the studies. ** The types of OC were provided by the
studies; multiple types were used in the Hendrix and Lu studies, and we did not segregate the data based on type. In both studies,
the types were clear cell adenocarcinoma, serous adenocarcinoma, endometrioid adenocarcinoma, and mucinous
adenocarcinoma.
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FIGURE 3.1: Summary of Sab expression levels in six OC gene expression studies.
Six studies were identified in the Oncomine repository that matched our criteria of a 2-fold
decrease in Sab expression and a p-value less than 10-4. The critical data of these studies
can be found in Table 1. We plotted the median value for Sab expression in normal tissue
(black circles) and ovarian cancer samples (gray squares) for each study, and the error bars
represent the 90th and 10th percentiles for each study. An asterisk (*) is used to indicate
studies with a p-value <0.005.

3.2. Ovarian cancer cell lines have distinct levels of Sab expression and mitochondrial
JNK signaling. To determine if the diminished Sab expression in the patient OC samples
affects chemosensitivity, we assessed Sab protein levels in OC cell lines. First, we
measured Sab expression in four commercially-available OC cell lines, Caov-3, PA-1, SKOV-3, and SW-626; human ovarian epithelial cells were used as a normal tissue control.
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Immunoblot analysis of Sab reveals that Caov-3 and SK-OV-3 lines have lower levels of
Sab than that of ovary epithelial cells. Caov-3 and SK-OV-3 had 33% and 48% less
expression, respectively (Figure 3.2A and 3.2B). Meanwhile, the expression of Sab was
significantly elevated in PA-1 and SW-626 cells (Figure 3.2A, top panel); PA-1 had an
average increased Sab expression of 6.7-fold that of ovarian epithelial cells, SW-626 was
4.2-fold higher (Figure 3.2A and 3.2B). -Tubulin was used as a cellular loading control
(Figure 3.2A, middle panel), while COX-IV was used as a control for mitochondrial
density (Figure 3.2A, bottom panel). Ponceau S staining of membranes was used to
normalize protein levels among cell types (Figure 3.2A). The results of four
immunoblotting experiments were quantified and normalized to Ponceau S in Figure 3.2B.
To evaluate if the differences in Sab protein levels among the four cell lines occurred on
the OMM or elsewhere in the cell, we performed subcellular fractionation to isolate
mitochondria and other subcellular compartments [33-35]. Immunoblotting of subcellular
fractions reveals that Sab is exclusively in the mitochondrial fraction for each of the four
OC cell lines as compared to nuclear, cytosolic, and microsomal fractions (Figure 3.2C).
We were unable to detect Sab at substantial levels in the ER, cytosolic or nuclear
preparations (Figure 3.2C). Furthermore, the relative purity of each compartment fraction
was assessed by monitoring the levels of nuclear (Histone H3), ER (Calnexin), lysosomal
(LAMP2), and peroxisomal (PEX19) contamination in the mitochondrial isolates (Figure
3.2C). Only preparations with greater than 80% purity were used in our analysis. The
relative levels of Sab were quantified and presented in Figure 3.2D. To examine if the
relative Sab levels in the OC cells reflected mitochondrial JNK levels, we performed an
immunoblot for JNK. JNK was not detected in any of the OC cell lines under normal
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culture conditions (Figure 3.2E). Equivalent mitochondrial loading and OMM loading in
each sample was assessed by the signal intensity of COX-IV and TOM20, respectively,
(Figure 3.2E). Because previous research has indicated that mitochondrial translocation of
JNK is dependent upon activation, we treated each of the four OC lines with 1M
staurosporine (STS) for 45 minutes and measured phosphorylated (active) JNK
(Thr183/Tyr185) levels in mitochondrial extracts. Upon treatment with 1M STS,
phospho-JNK levels on mitochondria increased in all four cell lines (Figure 3.2E); this was
reflected by an increase in the amount of total JNK in the mitochondrial isolates (Figure
3.2E). The amount of JNK localized on mitochondria of SK-OV-3 and Caov-3 cells were
62% and 47% less of the amount of JNK on the mitochondria of PA-1 cells (Figure 3.2E;
top panel). Also, SW-626 mitochondrial JNK levels were 21% less than JNK on PA-1
mitochondria (Figure 3.2E). Immunoblot analysis of whole cell extracts demonstrates that
there was no significant difference in JNK expression among the four OC cell types (Figure
3.2E; bottom panel), suggesting that the amount of JNK on mitochondria was dependent
upon the concentrations of Sab. As observed in our previous studies only the higher
molecular weight (54kDa) JNK band was present on mitochondria (Figure 3.2E; top panel);
accordingly, this band cross-reacted with the phospho-JNK-specific antibody in
mitochondrial preps from each of the four OC cell lines (Figure 3.2E, top panel).

72

73

FIGURE 3.2: The levels of Sab differ among OC cell lines and correspond to stressinduced mitochondrial JNK recruitment. (A) OC cell lines were grown under normal
cell culture conditions to ~80% confluency. The cells were lysed, and the proteins were
resolved by SDS-PAGE. Immunoblotting was performed to determine the relative
abundance of Sab with a-Tubulin and COX-IV serving as cellular and mitochondrial
loading controls. Ponceau staining of membranes was used to quantify the immunoblotting
results. (B) Quantification of Sab abundance from whole cell lysates in Figure 2A. (C)
Mitochondrial isolates were prepared from the four OC cell lines and assessed for the levels
of Sab by western blot analysis. TOM20 was used as an outer mitochondrial loading
control, while the relative contamination of other cellular compartments was assessed by
monitoring the levels of Calnexin (ER), Histone H3 (nucleus), PEX-19 (peroxisomes), and
LAMP2 (lysosomes). (D) The levels of Sab for each OC cell line were normalized to
mitochondria abundance (TOM20 levels) and quantified for seven independent biological
replicates. (E) The relative abundance of activated JNK on mitochondria was assessed in
the presence and absence of stress. The top panel examines the relative levels of total JNK
(JNK), activated JNK (P-JNK), with respect to Sab on mitochondria isolated from
untreated OC cells. The bottom panel shows the same proteins following treatment with
1mM staurosporine (STS) for 45 minutes. TOM20 was used as a mitochondrial loading
control for both panels. (F) In vitro kinase activity assays for JNK were performed on
mitochondria using either a c-Jun (1-79) or a Sab (335-435) peptide containing JNK
phosphorylation sites. Additionally, a Sab-peptide lacking JNK binding residues
(SabKIM1/2L-A(335-435) was used as a negative control substrate. SR-3306 (500nM), a
potent JNK inhibitor, was used to impair JNK activity during cellular stress and prevent
JNK translocation to mitochondria. An asterisk (*) is used to indicate studies with a pvalue <0.01 with respect to controls; meanwhile a double asterisk (**) is used to demark
differences between cell types and distinct treatments. Data are plotted as means and error
bars represent the standard deviation among at least three biological replicates.
To determine if JNK present on mitochondria following STS treatment was indeed active,
we lysed mitochondria isolated from each of the four OC cell lines in non-denaturing
conditions and then measured JNK activity towards c-Jun and Sab peptides as well as a
Sab mutant peptide (SabKIM1/2L-A(335-435)) incapable of binding JNK. Following exposure
to 1M STS, JNK activity increased on mitochondria from all four cell lines (Figure 3.2F).
However, JNK activity with respect to c-Jun and Sab peptides was increased over 10-fold
in PA-1 and SW-626 cells, while only a 2.5 and 3.5-fold increase in activity was observed
in SK-OV-3 and Caov-3 cells, respectively (Figure 3.2F). No kinase activity was observed
with the SabKIM1/2L-A(335-435) peptide (Figure 3.2F). The activity could be attributed to
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JNK as the introduction of 500nM JNK specific inhibitor SR-3306 prevented kinase
activity in the assay. Quantitation of western blot analyses can be found in Supplemental
Figure 3.2. This reinforces previous observations that imply JNK activation is required for
mitochondrial translocation.

To determine if JNK translocation was specific to STS, we treated cells with 25M
anisomycin for 30 minutes and measured mitochondrial JNK levels and activity. JNK
levels increased in all four OC cell lines, with greater amounts of JNK present on the
mitochondria of PA-1 and SW-626 compared to SK-OV-3 and Caov-3 (Supplemental
Figure 3). The JNK species on mitochondria cross-reacted with the phospho-specific JNK
antibody (Supplemental Figure 3). Similarly, the activity of JNK towards c-Jun and Sab
peptides in the mitochondrial fractions was greater in PA-1 and SW-626 cell compared to
SK-OV-3 and Caov-3 (Supplemental Figure 3). SR-3306 was used to demonstrate that
JNK was the kinase responsible for the activity. Taken together, these results demonstrate
that Sab concentrations on the OMM of OC cells may dictate the local magnitude of JNK
signaling.

3.3. OC cell lines with low Sab levels are resistant to chemotherapy agents: Because
mitochondrial JNK signaling on Sab is linked to apoptosis [33, 44-49], we measured the
chemosensitivity of the four OC cell lines to determine if Sab levels correlated to chemoresponsiveness. Using common and clinically relevant chemotherapeutic agents and OCtoxic regimens (Table 3.2), we assessed the potency of each with TO-PRO-3 staining and
near-infrared imaging (Supplemental Figure 4). The data presented in Table 3.2
summarizes the chemicals and IC50 values for each of the cells lines. SK-OV-3 and Caov-
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3 consistently had higher IC50 values than PA-1 and SW-626 cells. We also examined the
potency of paclitaxel/cisplatin treatment, an approach employed for resistant and refractory
tumors [5]. Similarly, SK-OV-3 cells and Caov-3 cells had considerably greater cellular
viability as assessed by TO-PRO-3

Table 3.2: Cell-based IC50 Values (M) for Chemotherapeutic Agents in OC Cell
Lines.
CHEMOTHERAPY

CAOV-3

PA-1

SK-OV-3

SW-626

PACLITAXEL

9.7  

0.11  

13.7  

0.57  

DOCETAXEL

0.45  

<0.01

1.22  

0.01  

DOXORUBICIN

0.41  

0.04  

0.5  

0.11  

ETOPOSIDE

28.9  

0.13  

10.9  

8.1  

CARBOPLATIN

48  

1.9  

65  

5.8  

CISPLATIN

34.5  

0.79  

60.2  

3.2  

ABT-263

189  

0.96  

215  

3.2  

ABT-727

8.9  

0.09  

15  

0.47  

OBATOCLAX

1.4  

0.07  

0.6  

0.09 

TW-37

1.69  

0.1  

0.8  

0.4 

Note: IC50 values are presented as means plus or minus one standard deviation of the mean.
The IC50s were determined using TO-PRO-3 staining and were confirmed by cell death
assays. For each assay, each dose over the range of 10nM to 1mM was performed in
quadruplet including the 0.01% DMF control. The means and standard deviations were
based on a minimum of three biological replicates.
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fluorescence following cisplatin/paclitaxel treatment when compared to PA-1 and SW-626
cells (Figure 3.3). Specifically, SK-OV-3 and Caov-3 had IC50 values greater than 10-fold
higher than PA-1 and SW-626 when treated with ABT-737, ABL-263, TW-37, and
Obatoclax mesylate (Table 2). To determine if Sab levels correlated to the cellular
sensitivities towards chemotherapeutic agents, we derived the Pearson’s coefficient with
respect to Sab levels (from Figure 3.2A) in the cell lines (Supplemental Figure 5). As
presented in Table 3.2, across the four OC cell lines, Sab levels were strongly correlated to
chemo sensitivity. The correlation curves and one-sided Pearson’s coefficients can be
found in Supplemental Figure 5 for each drug presented in Table 3.2.

FIGURE 3.3: Cisplatin/Paclitaxel treatment affects OC
cell lines differently. (A) TO-PRO-3 staining was used to
assess the viability of OC cell types following treatment
with vehicle (0.1% DMSO) or a combination of 0.25M
cisplatin and 0.1M paclitaxel for 72 hours. A
representative experiment with duplicates of each
treatment is shown to illustrate the technique. (B) The
quantified results of the cell viability are shown for each
OC cell line. The vehicle is the left bar, while the right bar
represents the relative fluorescence of cells treated with
cisplatin and paclitaxel. An asterisk (*) is used to indicate
studies with a p-value <0.01. Data are plotted as means and
error bars represent the standard deviation among at least
three biological replicates.
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3.4. OC cell mitochondria with high Sab expression are primed for apoptosis. Because
of the Sab-mediated JNK signaling is linked to Bcl-2 levels on mitochondria [33, 45, 49],
we measured the apoptotic potential in the four OC cell lines. To examine the extent of
apoptotic priming in each of the cancer cell lines, we first performed dynamic BH3
profiling [22, 27, 29] to assess the relative extent of priming. The addition of Bim BH3
peptide caused a rapid depolarization of mitochondrial membrane potential in all four OC
cell lines; however, the loss of JC-1 fluorescence was slower in SK-OV-3 cells than PA-1
(Figure 3.4A). Additionally, the PA-1 and SW-626 cells with higher levels of Sab
expression were found to have a greater percent depolarization than Caov-3 and SK-OV-3
cells that have relatively low Sab levels (Figure 3.4B). Consequently, the PA-1 and SW626 cells had a greater change in priming (%Priming) compared to Caov-3 and SK-OV3 cells (Figure 3.4C). Next, we verified the results of the dynamic BH3 profiling by
measuring the cytosolic levels of cytochrome c by immunodetection within cytoplasmic
subcellular fractions in the presence and absence of 500nM Bim-BH3 peptide (Figure
3.4D; quantified in 3.4E). The extent of cytochrome c present in the cytosol of OC cell
lines was modest compared to cells treated with 1M STS for two hours (Figure 3.4D and
3.4E). OC cells with low Sab expression (Caov-3 and SK-OV-3) had decreased
cytochrome c release into the cytosol compared to cells with higher Sab expression, PA-1,
and SW-626. To examine if the loss of mitochondrial membrane integrity was indeed due
to apoptotic priming, the relative levels of Bcl-2 proteins (Bcl-2, Bcl-xL, and Mcl-1), BH3only proteins (Bid, Bik, Bim, Bad, and Puma), and pro-apoptotic proteins (Bax and Bak)
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were measured (Figure 3.4F). The quantified data presented in Supplemental Figure 7
indicate that PA-1 and SW-626 cells have higher levels of pro-apoptotic BH3-only proteins
than Caov-3 and SK-OV-3 cells, which have higher levels of pro-survival Bcl-2 proteins.
This may indicate that ovarian cancer cells with elevated Sab-expression cells may be
primed for apoptosis.

3.5. Ectopic expression of Sab induces apoptotic priming. To directly determine if Sabmediated signaling contributes to apoptotic priming in ovarian cancer cell lines, we
ectopically expressed either RFP, Sab, or a Sab mutant incapable of binding JNK (Sab KIM1LA)

[35] (Figure 3.5A) in chemoresistant SK-OV-3 cells over the course of 72 hours (Figure

3.5B). By 72 hours, Sab was expressed five to seven-fold higher than SK-OV-3 cells that
are expressing RFP or mock-transfected cells (Figure 3.5B; quantified in Figure 3.5C).
Dynamic BH3 profiling reveals that SK-OV-3 cells expressing Sab have a greater percent
depolarization and change in depolarization compared to mock-transfected and RFPexpressing cells (Figure 3.5D), an effect that was not observed in cells expressing SabKIM1LA

(Figure 3.5D). Furthermore, analysis of cytosolic cytochrome c reveals that compared to

mock transfected and RFP-expressing SK-OV-3 cells, Sab expressing SK-OV-3 cells have
increased cytosolic cytochrome c (Figure 3.5E). This increase is not observed in SabKIM1LA-expressing

SK-OV-3 cells (Figure 3.5E). Additionally, the mitochondrial levels of Bcl-2

family proteins were assessed (Figure 3.5F). Ectopic expression of Sab in SK-OV-3 cells
changed the relative abundance of Bcl-2 and BH3-only proteins on mitochondria when
compared to mock transfected, RFP-expressing, and SabKIM1L-A-expressing cells (Figure
3.5G; quantified in Figure 3.5H).
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FIGURE 3.4: OC cells with high Sab expression are primed for apoptosis and
chemosensitive. (A) Dynamic BH3 profiling was used to evaluate the extent of mitochondrial
priming between PA-1 cells with high Sab expression and SK-OV-3 cells with low Sab levels.
Cells were treated with vehicle (0.1% DMSO) or 500nM BIM BH3-only peptide and JC-1
fluorescence was monitored. FCCP/Valinomycin was used to depolarize mitochondria in this
assay. (B) The percent depolarization and (2) the change relative priming (%Priming) were
calculated based on the dynamic BH3 profiling for each of the OC cell lines. An asterisk (*) is
used to indicate studies with a p-value <0.01. (D) The abundance of cytosolic cytochrome c
was measured using western blot analysis of cytosolic fractions taken from OC cells in the
absence (top panel) and presence of 500nM BIM peptide (bottom panel). GAPDH was used as
a cytosolic loading control. The relative fluorescence of cytosolic cytochrome c was quantified
(right panel). An asterisk (*) is used to indicate studies with a p-value <0.01. (E) Pro-survival
Bcl-2 protein levels were monitored on isolated mitochondria from each of the four OC cells
lines; specifically, Bcl-2, Bcl-xL, and Mcl-1 levels were measured, while TOM20 served as a
mitochondrial loading control. (F) Pro-apoptotic protein levels on mitochondrial were
measured by western blot analysis. Bim, Bad, Bak, and Bax were detected on isolated
mitochondria from the OC cell lines and COX-IV was used as a mitochondrial loading control.
Data are plotted as means and error bars represent the standard deviation among at least three
biological replicates.
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FIGURE 3.5: Artificially elevating Sab expression in resistant OC cells increases
vulnerability to chemotherapy. (A) A schematic representation of Sab showing the two
leucine residues in the KIM1 motif necessary for JNK binding. The bottom panel shows a Sabvariant (SabKIM1(L-A)) generated by site-directed mutagenesis that lacks the leucine residues
required for JNK binding. (B) Ectopic expression of Sab and Sab KIM1(L-A) in chemoresistant
SK-OV-3 cells was assessed using western blot analysis with TOM20 and Tubulin as loading
controls for mitochondria and whole cell respectively. (C) The relative levels of activated JNK
(P-JNK) and total JNK (JNK) on mitochondria (top panel) and in whole cell lysates (bottom
panel) were assessed in SK-OV-3 cells following 45 minutes of 1M STS treatment. (D)
Dynamic BH3 profiling of SK-OV-3 cells with and without ectopic expression of Sab was
performed in the presence of vehicle or 500nM BIM peptide, and treatment with
FCCP/Valinomycin was used as a depolarization control. (E) The %Depolarization and (F)
%Priming were calculated from the BH3 profiling for SK-OV-3 cells expressing either RFP,
Sab, or SabKIM1(L-A). An asterisk (*) is used to indicate studies with a p-value <0.01. (G)
Western blot analysis was used to assess the relative abundance of pro-survival (left panel) and
pro-apoptotic (right panel) in SK-OV-3 cells expressing either RFP, Sab, or SabKIM1(L-A). Data
are plotted as means and error bars represent the standard deviation among at least three
biological replicates.
3.6. Increasing Sab expression sensitizes SK-OV-3 cells to chemotherapies. Because Sab
levels may affect apoptotic priming, and we previously demonstrated that increasing Sab
sensitizes HeLa cells to toxic agents [35], we examined whether ectopic expression of Sab
enhanced the chemo-responsiveness of resistant SK-OV-3 cells towards cisplatin/paclitaxel
treatment. To assess cell death in mock-transfected SK-OV-3 cells, cells transfected with an
empty vector, or cells expressing either Sab or SabKIM1L-A, we utilized microscopic analysis of
Annexin V and PI staining (Figure 3.6A). Compared to mock-transfected cells and empty
vector cells, Sab-expressing SK-OV-3 cells had a considerable increase in the number of
apoptotic cells in the presence of 25M cisplatin and 10M paclitaxel after 72 hours (Figure
3.6B). Specifically, these cells had a marked rise in the number of late apoptotic cells (those
cells stained with both Annexin V and PI – Figure 3.5B). SK-OV-3 cells expressing the
MAPK-binding deficient mutant, Sab KIM1L-A, did not differ from mock-transfected and RFP
expressing SK-OV-3 cells (Figure 3.6B). To complement the microscopic analysis, we
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performed an assay to detect caspase 3 and 7 activity in the cells exposed to 25M cisplatin
and 10M paclitaxel. Mock-transfected and empty vector transfected cells had little caspase
activation following treatment with cisplatin and paclitaxel (Figure 3.6C); conversely, Sabexpressing cells had a substantial increase in caspase activity in the presence of
chemotherapeutic agents, which was comparable to SK-OV-3 cells treated with 1M of STS
for 24 hours (Figure 3.6C). Again, expression of Sab KIM1L-A in SK-OV-3 cells did not alter
caspase activity levels in response to 25M cisplatin and 10M paclitaxel treatment (Figure
3.6C). To determine if Sab-mediated signaling was involved in cisplatin and paclitaxel-induced
death in sensitive cell lines, such as PA-1, we incubated PA-1 with increasing amounts of either
Tat-Scramble or Tat-SabKIM1 and measured the extent of cell death following treatment with
0.25M cisplatin and 0.10M paclitaxel (Figure 3.6D). Inhibition of Sab-mediated signaling
with the Tat-SabKIM1 peptide prevented PA-1 cell death following cisplatin and paclitaxel
administration when compared to untreated and cells treated with Tat-Scramble peptide
(Figure 3.6D). PA-1 cells treated with a mutant Sab peptide, Tat-SabKIM1L-A, which cannot bind
MAPKs did not differ from cells treated with the Tat-Scramble peptide (Figure 3.6D). Again,
we verified the induction of apoptosis in PA-1 cells following 0.25M cisplatin and 0.10M
paclitaxel treatment by using a caspase activity (Figure 3.6E). PA-1 cells treated with 1M
Tat-SabKIM1 peptide had decreased caspase activity following treatment with chemotherapy
agents as compared to cells treated with 1M Tat-Scramble or Tat-SabKIM1L-A (Figure 3.6E).
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FIGURE 3.6: Inhibiting Sab-mediated signaling in sensitive OC cells enhances resistance.
(A) Fluorescent microscopy of a TUNEL assay performed on SK-OV-3 cells treated with
vehicle (0.1% DMSO) or 1M STS for 2 hours. Cells were stained with DAPI for total cell
number, while Annexin V and PI staining were used to detect early and late apoptosis
respectively. (B) The TUNEL assays were scored by counting the fluorescent cells in a field
of view, and based on fluorescence SK-OV-3 cells expressing either RFP, Sab, or SabKIM1(L-A)
were assessed for apoptosis levels in the presence and absence of 25M cisplatin and 10M
paclitaxel after 72 hours. (C) Caspase assays were performed using cell lysates obtained from
SK-OV-3 cells expressing RFP, Sab, or Sab KIM1(L-A) that were exposed to 1% DMSO,
Cisplatin/Paclitaxel for 72 hours, or 1M STS for 24 hours. (D) Chemosensitive PA-1 cells
with high Sab expression were surveyed for apoptosis using TUNEL assays in the presence
and absence of 0.25M cisplatin and 0.1M paclitaxel after 72 hours in the presence of
increasing concentrations of Tat-Scramble, Tat-SabKIM1, or Tat-SabKIM1(L-A) peptides. Both
early and late apoptotic cells were scored in these experiments. (E) Caspase assays were used
to assess the extent of apoptosis induced in PA-1 cells treated with cisplatin/paclitaxel and
1M of either Tat-Scramble, Tat-SabKIM1, or Tat-SabKIM1(L-A) peptides. STS was used as a
positive control for apoptosis. (F) To selectively impair Sab-mediated signaling in
chemosensitive PA-1 cells, we used shRNA-mediated gene silencing of Sab. Luciferasespecific shRNAs were used as a negative control, while two Sab-specific shRNAs were used.
Additionally, a version of Sab resistant to shRNA #1 was expressed in PA-1 cells treated with
San shRNA #1 as a rescue control. (G) The levels of Sab were assessed by western blot analysis
using COX-IV as a mitochondrial loading control and tubulin as a cellular loading control. (H)
A TUNEL assay was performed to assess the levels of apoptosis in cells treated with Luc or
Sab shRNAs and compared to a Sab rescue in PA-1 cells. (I) Caspase assays were employed
to indicate the level of apoptosis in the PA-1 cells treated with shRNAs. An asterisk (*) is used
to indicate studies with a p-value <0.01. A double asterisk (**) is used to demark differences
between cell types and distinct treatments. Data are plotted as means and error bars represent
the standard deviation among at least three biological replicates.
To confirm that the inhibition of apoptosis observed with the Tat-SabKIM1 peptide was due to
loss of Sab-mediated signaling, we silenced Sab expression in PA-1 cells using shRNAs
specific for Sab (Figure 3.6F; quantified in Figure 3.6G). Cell death induction was restored in
Sab-deficient PA-1 cells by ectopic expression of a shRNA-resistant Sab construct (Figure
3.6F and 3.6H) [35]. Additionally, silencing Sab expression in PA-1 cells impaired caspase
activation when compared to cells expressing a control shRNA (Figure 3.6I), and expression
of a shRNA-resistant Sab restore caspase activity following 0.25M cisplatin and 0.10M
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paclitaxel treatment. Taken together, these results suggest that Sab facilitates signaling
necessary to induce apoptosis in OC cells.

4.Discussion
Mitochondrial JNK signaling on the OMM scaffold protein Sab has been shown to be an
instrumental event in the induction of mitochondria-induced cell death; furthermore,
altering the concentration of Sab-mediated JNK signaling has been shown to affect
chemosensitivity in tissues (brain and heart) and cancer cells. In our current study, we
extend these observations by demonstrating that chemoresistant cancer cells have
diminished Sab expression compared to normal tissue, and restoring or enhancing Sab
levels on the OMM is critical to reestablishing proper apoptotic signaling in OC cell lines.
Our analysis of six independent OC transcriptome analyses [38-43] found that Sab mRNA
levels were reduced over 5-fold when compared to normal tissues (Figure 3.1, Table 3.1).
Previous studies have demonstrated in various tissues and cell lines that diminished Sabmediated signaling prevents apoptosis [33, 36, 47, 48, 50, 51]. To date, there are no
published reports regarding the transcriptional regulation of Sab. It stands to reason that
the decreased reliance on mitochondrial health status and the suppression of apoptotic
mechanisms in cancer cells [19] may be partly responsible for the reduction in Sab
expression. Indeed, we recently described that JNK-deficient murine embryonic fibroblasts
(MEFs) had a significant decrease in Sab on the OMM compared to wild-type MEFs [35].
In our opinion, this would suggest that perturbations in signal transduction pathways,
specifically those responsible for apoptosis, may be instrumental to the diminished Sab
levels in OC.
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Intriguingly, one OC patient from The Cancer Genome Atlas repository [42] had a Saboverexpression phenotype; however, the genomic sequence of Sab from this patient
possessed premature termination site, which truncated the protein at residue 379 (Sab is
normally 455 amino acids in length). The loss of the C-terminal portion removes the two
kinase interaction motifs (KIMs) responsible for mitochondrial MAPK signaling. Without
the KIMs, it is unlikely that this Sab variant would have any impact on apoptotic induction,
as previous studies have demonstrated that mutation of the KIMs that disrupt MAPK
binding prevent the induction of cell death.

We demonstrated that the relative levels of Sab correlate to chemo-responsiveness in OC
cells. Over-expression of Sab improved the chemosensitivity of resistant SK-OV-3 cells;
meanwhile, inhibiting Sab-mediated signaling with the Tat-SabKIM1 peptide or silencing
Sab expression increased chemoresistance in vulnerable PA-1 cells (Figure 3.2 and 3.5).
These effects were mediated by the relative levels of JNK on mitochondria. JNK signaling
has long been implicated in apoptotic responses [52]. JNK signaling can contribute to
apoptosis through the combination of nuclear and cytosolic/mitochondrial mechanisms.

The primary mitochondrial alteration facilitated by Sab-mediated JNK signaling in OC
cells was the change in Bcl-2/BH3-only proteins at mitochondria (Figure 3 and 4). Previous
research establishes this possibility, as JNK can directly phosphorylate Bcl-2 and BH3only proteins affecting their functions and localizations [53]. We observed a marked
decrease in mitochondrial Bcl-2 levels, an event previously noted in breast cancer cells
treated with paclitaxel [54, 55]. Following stress, such as chemotherapy, JNK can
phosphorylate Bcl-2 on Ser70 inducing its migration from the OMM [33, 56]. Furthermore,
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JNK can impair Bcl-xL activity by phosphorylating Thr47 and Thr115 [45]. Enhancing
the amount of Sab on the OMM would increase the concentration of activated JNK that
could modify Bcl-2 proteins and hasten the impairment of anti-apoptotic mechanisms on
mitochondria.

JNK can directly phosphorylate BH3-only proteins and increase their pro-apoptotic
potential. During UV-induced apoptosis JNK has been shown to phosphorylate Bim and
Bmf [24, 56, 57]. This phosphorylation causes Bim and Bmf to dissociate from dynein and
myosin V motor complexes and activate Bax and Bak to initiate apoptosis. Furthermore,
phosphorylation of Bim by JNK can complement JNK’s phosphorylation of Bcl-2 and BclxL because Bim can bind and neutralize Bcl-2 and Bcl-xL to promote apoptosis as well.
Additionally, JNK can phosphorylate Bad on Ser128, which promotes apoptosis [58]. Bad,
similar to Bim, can promote apoptosis by inhibiting Bcl-2 proteins. JNK can improve Bad
activity by phosphorylating 14-3-3, which causes the release of Bad from the scaffold
[59]. JNK can also affect the BH3-only proteins of the extrinsic pathway of apoptosis at
the mitochondrial level. JNK can induce the cleavage of Bid, thereby elevating the levels
of t-Bid, which will, in turn, activate Bax and Bak [60, 61]. During TNF--evoked
apoptosis in HeLa cells, JNK activity induces a caspase 8-dependent cleavage of Bid that
produces the product jBid that promotes the release of Smac/DIABLO [62]. In addition to
the direct modulation of Bcl-2 function, mitochondrial JNK signaling facilitated by Sab
would also enhance the activity of BH-3 only proteins contributing to apoptosis in OC cells
treated with chemotherapy.

89

We have previously demonstrated that increasing Sab levels in mammalian cells can
increase the vulnerability towards toxic agents. First, we demonstrated that the sub-chronic
exposure to the chemosensitizer LY294002 increased Sab levels on the OMM, which led
to an increase in mitochondrial JNK signaling and induction of apoptosis [35]. This data
combined with our current study would suggest that increasing Sab levels would be a useful
technique to improve chemo-responsiveness in cancer cells. However, we have recently
reported that elevated Sab levels in the heart can increase the risk for cardiotoxicity
following chemotherapy [36]. We show that artificially enhancing Sab in cardiomyocyte
cell lines sensitized the cells to imatinib [14]. One may anticipate that targeted methods to
selectively up-regulate Sab expression in OC tumors may be a safer approach to sensitize
cancer cells than that of widespread Sab increase in the body.

We propose that Sab levels may be utilized better as a prognostic biomarker to guide the
selection and magnitude of therapy for OC patients. Specifically, low Sab concentrations
in a tumor biopsy or resection may suggest a more rigorous therapeutic regimen; whereby,
high Sab levels may allow for a less ambitious and toxic approach to treating patients.
Nonetheless, cancer, especially OC, are complex conditions and Sab concentrations may
need to be considered in the cellular context of the tumor for choosing the most efficacious
therapeutic approach. Because little is known regarding the regulation of Sab expression,
future studies in our group will be focused on understanding the molecular mechanisms
responsible for controlling Sab levels on the OMM.

Our current study reinforces the important role that scaffold proteins play in regulating the
cell signaling responses, especially how scaffold proteins, such as Sab, can influence the
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magnitude and outcomes at specific subcellular sites within cells. We demonstrate that
increasing the concentration of a specific OMM scaffold protein can enhance signaling
pathways on mitochondria and alter organelle and cellular physiology. Specifically, we
have demonstrated that increasing Sab levels in OC cells increases mitochondrial JNK
signaling and apoptotic priming, which enhances the vulnerability of OC cells to
chemotherapy agents. Moreover, we uncovered that Sab levels are decreased in OC patient
samples, and restoring Sab levels in OC cells with low Sab expression enhances chemoresponsiveness. Thus, assessing Sab expression in the context of genetic and histological
testing, including dynamic BH3 profiling may be a useful prognostic tool for OC.
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Chapter 5
SAB CONCENTRATIONS INDICATE CHEMOTHERAPEUTIC
SUSCEPTIBILITY IN UTERINE CANCER CELLS
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1. Introduction
Uterine cancer (UC), the most common gynecological cancer in developed countries [1],
is a malignancy of the uterus that commonly arises in the endometrium as adenocarcinoma
[2]. There are approximately 55,000 new cases of UC each year, which accounts for ~3.3%
of new cancer cases and the prevalence of UC is increasing [1]. UC patients have an 81.7%
5-year survival rate; accordingly, the UC survival rate drops to 16.9% for metastatic disease
[3]. Treatment options for uterine cancer include surgery with radiotherapy and
chemotherapy [4, 5]. Because of the favorable survival rate, the underlying causes of
treatment resistance in UC have not been extensively investigated. However, metastatic
UC is typified by treatment resistance [6]; specifically, there is substantial chemoresistance toward megestrol acetate, the approved drug for treatment of UC [7].
Additionally, UC is often a disease of older women, whereby, most UC diagnoses are made
between the ages of 45 and 75 years of age [8]. Thus, safer therapeutic alternatives may
need to be considered due to the increased likelihood of toxic off-target effects in older
patients [8]. Consequently, understanding the molecular mechanisms driving UC
oncogenesis and resistance will be instrumental in developing rational therapies targeting
unique aspects of UC pathophysiology to develop more efficacious and safer UC
treatments.
Mitochondria are highly integrated organelles that regulate a myriad of cellular processes
including cell death [9]. Paramount to mitochondrial apoptotic events are the Bcl-2 family
of proteins, which control the cell death potential of mitochondria [10]. BH3-only proteins,
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members of the Bcl-2 family, facilitate apoptotic programming by sequestering the prosurvival Bcl-2 proteins and mediating the formation of the Bax-Bak pore [11]. The
formation of the Bax-Bak pore causes mitochondrial outer membrane permeabilization
(OMMP), which allows for the release of pro-apoptotic components from the mitochondria
(i.e. cytochrome c, endonuclease G, etc.) [12, 13]. Recently, studies have demonstrated that
the levels of BH3-only proteins correlate to chemo-responsiveness [14-19]; wherein, high
BH3-only levels conferred chemo-sensitivity due to elevated OMMP, while low BH3-only
levels corresponded to chemo-resistance in vitro and in vivo [20-24]. Further, chemical
induction of BH3-only proteins in chemo-resistant cells improved the chemoresponsiveness of several cancer cell types [18, 20]. However, the mechanism responsible
for enhanced BH3-only levels in certain cancers remains elusive.
Recently, we demonstrated that the chemosensitizer LY294002 [25] altered mitochondrial
signaling to enhance the effectiveness of radiotherapy and chemotherapeutic agents [2527]. In cervical cancer cells (HeLa cells), administration of low-dose LY294002 increased
the concentration of a mitochondrial scaffold protein Sab, which facilitated chemosensitization [28]. Previously, Sab-mediated signaling events have been linked to
mitochondrial dysfunction and the induction of apoptosis in numerous cell types and under
a myriad of conditions [29-34]. Sab facilitates c-Jun N-terminal Kinase (JNK) signaling on
the outer mitochondrial membrane (OMM) [29, 35, 36]. Specifically, activated JNK
isoforms can interact with one of two kinase interaction motifs (KIM1/2) neat the Cterminus of Sab, and ablation of essential residues in the KIM binding sites or use of KIM101

motif mimicry can prevent JNK translocation to mitochondria along with subsequent
organelle dysfunction and apoptosis [28, 29, 35-37]. Mitochondrial JNK signaling induces
apoptosis through the manipulation of Bcl-2 family proteins via posttranslational
modifications [29, 38-43]. The magnitude of local JNK signaling on Bcl-2 proteins in
tumors determines the capacity of individual cells to induce apoptosis [44, 45].
Furthermore, chemotherapeutic agents have been shown to be potent inducers of
mitochondrial JNK signaling events [28, 40, 46, 47]. Based on these studies, enhancing
JNK signaling on mitochondria could be a means to improve therapeutic responsiveness in
UC patients.
Because the abundance of scaffold proteins at specific subcellular sites dictate the
biological outcomes of signaling events [48-50], the goal of the current study is to
determine if changes in Sab concentrations affect mitochondrial physiology and the
induction of apoptosis in UC cells. To investigate this possibility, we performed secondary
data analysis of existing gene expression studies from patients with UC. After observing
that Sab levels were reduced in UC patient samples with advanced and recurring disease,
we assessed mitochondrial physiology in a metastatic-derived (AN-3-Ca) and a primary
site-derived (SKUT-1) cell line. We found that Sab-levels were increased in the primary
site line compared to the metastatic line. This difference was reflected by the resistance of
An-3-Ca cells to common chemotherapeutic agents. The AN-3-Ca resistance to
chemotherapy was mitigated by overexpressing Sab in the cells; contrariwise, silencing
Sab in chemosensitive SKUT-1 cells promote resistance to chemotherapy agents. After
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observing this evidence, these results suggest that alteration of Sab expression in late-stage
UC may be responsible for chemoresistance.
2. Materials and methods
Gene Expression Analysis: Secondary data analysis was performed to determine the
relative levels of Sab expression in UC. The expression of Sab (SH3-binding protein 5;
SH3BP5) was examined using the Oncomine database (http://www.oncomine.org) in
October 2017 [51]. By querying available endometrial cancer datasets that included Sab,
we compared experimental data from normal and malignant tissue. The data were compiled
across the independent studies. Data are presented as mean fold changes between
endometrial cancer and control samples or distinct types of endometrial cancers.
Materials: AN-3-Ca (HTB-111) and SKUT-1 (HTB-114) cells were obtained from
American Type Culture Collection (Manassas, VA), and metabolic testing reagents were
acquired from Seahorse Biosciences (Boston, MA). Antibodies were procured from Cell
Signaling Technologies (Danvers, MA) unless indicated otherwise. Chemotherapeutic
agents and general laboratory supplies were purchased from Fisher Scientific (Pittsburgh,
PA) unless alternatively noted below. Near-infrared detection reagents were purchased
from Li-Cor Biosciences.
Cell Culture: AN-3-Ca and SKUT-1 cells were grown in Eagle Minimum Essential
Medium (EMEM) supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin,
10g/mL streptomycin, and 5g/mL plasmocin (Invivogen). The cells were cultured at
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37C under humidity with 5% CO2. The cells were counted using the TC10 counter
(BioRad) in the presence of Trypan blue.
Determining IC50 for drugs: To examine the relative effectiveness of drugs towards a
particular cell line, we calculated IC50 for drugs in AN-3-Ca and SKUT-1 cells [28]. Cells
were plated in a black-walled 96-well plate at a density of 2.0x105 cells per well and grown
overnight. We tested common and existing chemotherapeutic agents for UC; this group of
compounds included megestrol acetate, ABT-737, cisplatin, doxorubicin, mitomycin C,
and paclitaxel. The cells were treated with increasing concentrations of the drug (ranging
from 0.1nM to 100M on a log10 scale) for 72 hours and were then washed, fixed, and
stained with TO-PRO-3 for 45 minutes at room temperature. The plate was imaged using
the Odyssey CLx imager (Li-Cor Biosciences), the fluorescence of each well was
determined using the ImageStudio 2.0 software (Li-Cor Biosciences), and IC50s were
calculated using the GraphPad Prism7© software.
Western blot analysis: Protein analysis from cells was performed as described in our
previous works [28-30]. Briefly, AN-3-Ca and SKUT-1 cells were plated in either 6-well
plates or 35-mm2 dishes. Following treatments, cells were washed twice in phosphate
buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, and 1.8mM KH2PO4)
and lysed in radioimmunoprecipitation assay buffer (RIPA; 50mM Tris-HCl, pH 8.0,
150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS) supplemented with 1mM
phenylmethanesulfonyl fluoride (PMSF) and Halt Protease and Phosphatase Inhibitor
Cocktails (Thermo Scientific). Cells were incubated while gently rocking at 4°C for five
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minutes, and then transferred to a sterile micro-centrifuge tube. After two minutes on ice,
cell disruption was completed using sonication. The lysate was cleared by centrifugation
at 14,000 × g for 15 minutes. The protein in the cell lysates was quantified using a BCA
kit (Pierce BCA Protein Assay Kit) in clear 96-well plates according to the manufacturer’s
protocol using the Biotek Synergy H1 Microplate Reader. Proteins were then resolved by
SDS-PAGE and transferred onto low fluorescence PVDF membranes. Membranes were
placed in blocking buffer comprised of PBS supplemented with either 5% non-fat milk (for
standard blots) or 5% bovine serum albumin (BSA; for phosphor-specific blots) and
incubated for at least one hour at room temperature (RT) or overnight at 4°C. The
membranes were incubated in PBS containing 0.1% Tween 20 (PBST) and either 5% nonfat milk or BSA in the presence of primary antibodies for at least 2.5 hours (RT) or
overnight (4oC) while gently rocking. Primary antibodies specific for Sab (Novus
Biologics, #H00009467-M01), Bcl-2 (Cell Signaling Technologies (CST), 2870), Bcl-xL
(CST, 2764), Mcl-1 (CST, 5453), Bad (CST, 9239), Bik (CST, 4592), Bim (CST, 2933),
Bid (CST, 2002), PUMA (CST, 12450), Bax (CST, 5023), Bak (CST, 12105)Actin (CST,
4970),and α-tubulin (CST, 2144) were used at dilutions of 1:1000 for these studies.
Membranes were washed three times for five minutes in PBST. Membranes were incubated
with secondary antibodies in the appropriate blocking buffer at a ratio of 1:20,000 for one
hour at RT gently rocking. The following secondary antibodies were used in the
experiments below: IRDye 680RD Goat anti-Rabbit (926-32211) and IRDye 800CW Goat
anti-Mouse (926-68070) (Licor Biosciences). Membranes were again washed three times
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for five minutes in PBST. Membranes were analyzed using fluorescence detection using
the Odyssey CLx near infrared scanner (Licor Biosciences). The corresponding bands on
the western blots were quantified and normalized using the Image Studio 2.0 software
(Licor Biosciences). The fluorescence of specific bands of interest were divided by the
fluorescence of the loading control band to equilibrate signal strength and loading. The
resulting signal was then normalized by dividing the signals from treated samples by
respective untreated or normal tissue control signals for each experiment.
Metabolic Analysis: Cellular metabolism was assessed by measuring the extracellular
acidification rate (ECAR) and the oxygen consumption rate (OCR) of UC cells using the
Seahorse Biosciences XF-96 extracellular flux analyzer [52]. Cells were plated in XF-96
analyzer plates at 1.0 x104 cells per well and treated as described below. Basal glycolysis
rates (ECAR) were achieved by supplementing glucose-free assay with 10mM glucose
(Glc). After 10 minutes, the ECAR was measured; simultaneously, OCR was measured to
determine the amount of glucose oxidation in each treatment group. Then 1.0M
oligomycin was added to inhibit ATP-dependent respiration and induce maximum
glycolysis (or ECAR). While treatment with 100M 2-DOG was used to impair glucose
utilization and oxidation. For assessing oxygen consumption and substrate oxidation, cells
were placed in nutrient-free media, and OCR was measured before injection of either
10mM glucose or 5mM glutamine. Then, a mitochondrial respiratory profile was created.
Briefly, basal OCR was measured for 20 minutes; next, cells were treated with 1M
oligomycin for 10 minutes, and then OCR was measured again to determine ATP106

independent respiration rates. Following that measurement, 1M uncoupler (FCCP) was
added for 10 minutes, and then maximum OCR was measured. Finally, 1M of rotenone
and antimycin A was added for 10 minutes to completely inhibit mitochondrial respiration,
and OCR was measured to assess the amount of non-mitochondrial respiration. From these
measurements, we derived respiratory parameters, including spare respiratory capacity as
previously described. All rates were calculated from a minimum of six wells per
experiment. Data were either normalized to cell number.
Manipulation of Sab Expression: We transiently transfected UC cells with plasmids
designed to express Sab (pLOC:Sab), red fluorescent protein (RFP; pLOC:RFP), or a Sab
mutant lacking MAPK binding motifs (pLOC:SabKIML/A) to evaluate the impact of
increasing Sab levels. Plasmid DNA and FugeneHD (Promega) were combined in
Optimem (Invitrogen) at a ratio of 1:6 and incubated for 15 minutes at RT before addition
to culture. Eight hours after the addition of the transfection complex to media, the media
was exchanged. Protein levels were assessed by western blot analysis at 72 hours posttransfection only cells demonstrating more than four-fold increases in Sab levels were used.
To decrease Sab expression, SKUT-1 cells were transiently transfected with pLKO.1
plasmids containing shRNAs either a luciferase-specific shRNA (control) or a shRNA for
Sab that demonstrated over 85% silencing in 72 hours. Ectopic expression of a shRNAresistant form of Sab (previously described in (Chambers, TP, 2015)) was used to rescue
Sab levels in SKUT-1 cells silencing Sab. Briefly, 1.5x104 cells were plated in a 96-well
plate, or 1.5x105 cells were plated a day before transfection in 35-mm dishes for
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experiments. Plasmids were mixed with FugeneHD (Promega) at a 6:1 ratio per
manufacturer’s recommendations and added to cells for up to 72 hours. Protein levels were
determined by western blotting as described above.
Replicates and Statistics: Biochemical and other cellular measures were done with a
minimum of six experimental replicates. Mitochondrial and protein analysis experiments
were performed on a minimum of three biological replicates. To determine statistical
significance, Mann-Whitney analysis was employed for significance between treatments
and a Wilcoxon match pairs test was used to compare groups. One-way analysis of variance
(ANOVA) was used to compared data across studies. Statistical significance is indicated
by an asterisk in figures in which the P-value is less than 0.05. Data are displayed in figures
as means with error bars representing plus and minus one standard deviation.
3. Results
3.1. Sab expression is diminished in late-stage uterine cancer and recurrent disease.
To determine if changes in Sab levels may occur in UC, we used existing studies of
endometrial cancer gene expression from the Oncomine repository [51]. We segregated
these data into clinical stage first to determine if Sab concentrations changed during
progression of the disease. In Figure 4.1A, Sab expression is significantly decreased (nearly
6-fold) in Stage 4 samples, but not in the other stages of the disease. Similarly, our analysis
of recurrent tumors versus patient samples from non-recurrent disease, demonstrate that
Sab levels are markedly decreased (approximately 4-fold) in recurrent tumors compared to
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non-recurrent (Figure 5.1B). In long-term recurrent disease, Sab mRNA levels are even
lower (Figure 5.1B) at five years. This data suggest that Sab expression is diminished in
advanced and recurrent UC.

Figure 4.1: Secondary analysis of Sab expression from uterine cancer microarray studies. (A)
The amount of Sab mRNA was examined from previous studies, and the patient samples were
segregated based on the reported stage of the cancer. The distinct types of uterine cancer were
grouped into clinical classifications. An asterisk (*) indicates a difference as determined by oneway Analysis of variance (ANOVA). (B) For samples with available data regarding the recurrence
of disease, Sab expression levels were assessed in regards to disease recurrence at one and five
years. An asterisk (*) indicates a difference between non-recurring and recurring tumors according
to the Wilcoxon matched pairs test. Data are displayed as means with error bars representing plus
and minus one standard deviation.

3.2.Metastatic AN-3-Ca cells have reduced chemosusceptibility:
Because of the difference in Sab expression observed in Stage 4 disease, we performed
comparisons of primary site and metastatic UC cell types. We obtained SKUT-1 and AN3-Ca cells that were derived from primary site and metastatic tumors, respectively. First,
we assessed the relative chemosensitivity of the two lines to observe potential differences
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using a battery of chemotherapeutic agents. Each drug reflects a different mode of death
induction in cancer cells providing insight into potential defects in cell death signaling. In
Table 4.1, the IC50s for megestrol acetate, ABT-737, cisplatin, doxorubicin, mitomycin C,
and paclitaxel are presented. The metastasis-derived AN-3-Ca cell line consistently
required more drug to induce cell death compared to primary site-derived SKUT-1 cells.
3.3. SKUT-1 cells and AN-3-Ca cells are metabolically distinct:
Because the trend in the IC50 data may suggest a difference in the induction of apoptosis, a
mitochondrial process, we examined whether mitochondrial function differed between the
two lines. Using respirometry, we measured the respiratory profile of the two cell lines and
found that AN-3-Ca cells had a greater oxygen consumption rate (OCR) than SKUT-1 cells
(Figure 4.2A). This was reflected by higher basal respiration (Figure 4.2B) and a greater
respiratory capacity (Figure 4.2C) when compared to SKUT-1 cells. Additionally, AN-3Ca cells had a higher incidence of uncoupling than SKUT-1 cells (Figure 4.2D), and
overall, AN-3-Ca cells had a greater OCR/ECAR ratio (Figure 4.2E). Next, we analyzed
the metabolic parameters related to glycolysis in the two cell lines by assessing the
extracellular acidification rate (ECAR) (Figure 4.2F). We found that SKUT-1 cells had a
greater rate of glycolysis than AN-3-Ca cells (Figure 4.2G). Additionally, when 1M
oligomycin was added to achieve maximum glycolysis, it was found that the
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Table 4.1: IC50 values for Common Chemotherapy agents for UC cell lines

Figure 4.2: Mitochondrial metabolism differs between AN-3-Ca and SKUT1 cells. (A)
Respiratory profile of AN-3-CA and SKUT-1 cells was measured using the Seahorse XF-96
extracellular flux analyzer. B. Basal respiration, C. Spare respiratory capacity, D. Uncoupling, E.
Oxidative ratio, F. Extracellular acidification rate, G. Glycolysis, H. Glycolytic Capacity, I.
Glycolytic reserve, J. Proton leak were measured. Data are displayed as means with error bars
representing plus and minus one standard deviation.
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Figure 4.3: Sab concentrations differ between metastatic AN-3-Ca cells and primary site
SKUT-1 cells. (A) A representative western blot analysis of AN-3-Ca and SKUT-1 cells to assess
the relative levels of Sab on mitochondria. COX-IV was used as a mitochondrial loading control.
(B) Quantification of four replicate analysis was performed using Image Studio 2.0. An asterisk (*)
indicates a difference (P<0.05) between cell lines as determined by a Mann-Whitney test. Data are
displayed as means with error bars representing plus and minus one standard deviation.
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Figure 4.4: Increasing Sab concentrations restore chemosensitivity in AN-3-Ca cells. (A)
Western blot analysis of AN-3-Ca and SKUT-1 cells to assess the relative levels of Bcl-2 protein
levels. COX-IV was used as a mitochondrial loading control. (B) Ectopic expression of either RFP
or Sab was assessed by western blot analysis. Additionally, Bcl-2 and Bim levels were measured
with COX-IV serving as an organelle loading control. (C) Quantification of the changes in Sab,
Bcl-2, Bim, and Bid were performed using Image Studio 2.0. Differences (P<0.05) between paired
samples was determined with a Wilcoxon matched pairs test, which are indicated by an asterisk
(*). Data are displayed as means with error bars representing plus and minus one standard deviation.

two cell lines had a similar capacity for glycolysis (Figure 4.2H); however, SKUT-1 cells
had a greater glycolytic reserve (Figure 4.2I).
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Intriguingly, AN-3-Ca cells had a greater proton leak than SKUT-1 cells (Figure 4.2J).
Taken together, the studies suggest that AN-3-Ca cells and SKUT-1 cells have distinct
mitochondrial metabolic profiles.
3.4 AN-3-Ca cells have diminished Sab concentrations:
Because our previous work demonstrated that Sab-mediated events could affect chemoresponsiveness and metabolism in human cancers, we measured the relative abundance of
Sab in the primary-site-derived SKUT-1 cells and metastatic AN-3-Ca cell lines. In Figure
4.3A, western blot analyses revealed a significant increase in Sab concentrations in the
SKUT-1 cells compared to AN-3-Ca cells. The relative Sab fluorescence in these cells was
normalized to the mitochondrial loading control, cyclo-oxygenase IV (COX-IV), a
component of respiratory complex IV. Using semi-quantitative analysis, we found that AN3-Ca cells had ~8-fold less Sab than SKUT-1 cells (Figure 4.3B).
3.5 AN-3-Ca cells have increased anti-apoptotic Bcl-2 proteins resulting from
diminished Sab levels:
Because of the chemo-responsive and metabolic differences along with the distinct Sab
concentrations between the two cells, we assessed the expression of hallmark Bcl-2
proteins in AN-3-Ca and SKUT-1 cells. The specific apoptotic proteins we examined were
the anti-apoptotic Bcl-2 family proteins: Bcl-2 and Bcl-xL. We also looked at pro-apoptotic
BH3-only family proteins: Bid, Bim, Bad. In Figure 4A, AN-3-Ca have higher antiapoptotic Bcl-2 concentrations (Bcl-2, Bcl-XL) and lower pro-apoptotic Bcl-2 protein
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levels (Bid, Bim, and Bad) compared to SKUT-1 cells (quantified in Figure 4.4C). To test
whether the shift in Bcl-2 proteins in AN-3-Ca cells was due to diminished Sab
concentrations, we overexpressed Sab or red fluorescent protein (RFP) in AN-3-Ca cells
to determine the effect on Bcl-2 protein levels (Figure 4.4B). Increasing the relative
abundance of Sab in AN-3-Ca cells resulted in a significant decrease in Bcl-2 protein levels
that was not observed in cells expressing RFP (Figure 4.4B). Furthermore, elevating Sab
concentrations in AN-3-Ca cells increased the relative abundance of Bim, an effect that
was not found in RFP-expressing AN-3-Ca cells (Figure 4.3B). This occurred without a
significant change in mitochondrial protein levels, as indicated by COX-IV detection
(Figure 4.3B). To determine whether increasing Sab altered the susceptibility of AN-3-Ca
cells to chemotherapeutic agents, we examined cell viability following treatment with the
previously introduced chemotherapeutic agents (Table 5.2). AN-3-Ca cells overexpressing
cells were significantly more susceptible to chemotherapy agents than cells expressing RFP
or non-transfected AN-3-Ca cells (Table 4.2). Collectively, these results demonstrate that
increasing Sab levels alters the chemosensitivity of UC cells by manipulating Bcl-2 family
protein levels on mitochondria.
3.6 Silencing Sab expression in SKUT-1 cells induces chemoresistance:
To examine if altering Sab expression impacted the sensitivity of primary-site derived cells
to chemotherapy agents, we introduced a plasmid into SKUT-1 cells that expressed either
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Table 4.2: IC50 values for Chemotherapy agents in AN-3-Ca cells with increasing Sab
expression.

a control (luciferase-specific) small-hairpin RNA (shRNA) or a Sab-specific shRNA. We
assessed the ability of the shRNAs to affect Sab abundance after 72 hours; wherein, the
Sab shRNA, but not the control shRNA, reduced Sab levels to a concentration comparable
to AN-3-Ca cells (Figure 4.5A). These differences were quantified in Figure 4.5B. To
determine if silencing Sab expression, impaired JNK translocation to mitochondria, we
purified mitochondria from cells that were treated with 0.01% DMSO or 25M
staurosporine (STS) to induce JNK translocation to mitochondria. In the presence of
DMSO, JNK did not become activated or translocate to mitochondria in either cell line or
the presence of the shRNAs
We expressed a shRNA-resistant version of Sab as a potential rescue for Sab-mediated
events (Figure 4.5C). However, the addition of STS triggered JNK translocation to
mitochondria in SKUT-1cells, as well as in SKUT-1 cells expressing the control and Sab
shRNAs (Figure 4.5C, bottom panel). The relative abundance of mitochondrial JNK (P-
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JNK) corresponded to the levels of Sab in each cell type (Figure 4.5C), which was
quantified as (Figure 4.5C, top panel).

Figure 4.5: Silencing Sab in SKUT-1 cells make them chemoresistant. (A) Western blot analysis
of AN-3-Ca and SKUT-1 after silencing Sab in SKUT-1 cell to assess Sab levels. COX-IV was
used as a mitochondrial loading control. (B) Quantification of Sab. (C) Western blot analysis of
active JNK in SKUT-1 cells after silencing of Sab. (D) Quantification of P-JNK was performed
using the Image Studio 2.0 Software. Differences (P<0.05) between paired samples were
determined using a Wilcoxon matched pairs test, which are indicated by an asterisk (*). (E) Western
blot analysis of Bcl-2 and Bim in SKUT-1 cells after silencing of Sab. (F) Relative cytososlic
cytochrome C released. Data are displayed as means with error bars representing plus and minus
one standard deviation.
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well to demonstrate that there was significantly less mitochondrial JNK in SKUT-1 cells
silencing Sab and rescued by expressing the shRNA-resistant Sab (Figure 4.5D). We also
examined critical JNK-regulated Bcl-2 proteins, Bcl-2, Bim, and Bid, in the presence and
absence of the Sab shRNA. Following STS-exposure, Bcl-2 levels decreased in SKUT-1
cells, but not in cells expressing the Sab shRNA (Figure 4.5E). Mitochondrial Bcl-2 was
restored by expressing the shRNA-resistant Sab (Figure 4.5E). Contrariwise, the
concentrations of Bim and Bid increased following STS treatment in SKUT-1 cells, but
not in cells with the shRNA for Sab (Figure 4.5E). Again, the matriculation of Bim and
Bid to mitochondria was rescued by expressing the shRNA-resistant form of Sab in SKUT1 cells (Figure 4.5E). To determine if the changes in Sab levels affected the apoptotic
potential in SKUT-1 cells, we measured the amount of cytosolic cytochrome c following
treatment with STS in SKUT-1 cells with and without Sab-mediated signaling. Again,
silencing Sab results in less cytosolic cytochrome c release into the cytosol following STStreatment, and introducing the shRNA-resistant Sab restores the induction of apoptosis in
SKUT-1 cells (Figure 4.5F). These data reiterate that Sab is a crucial element of apoptotic
signaling in UC cells.
To determine if indeed reducing Sab levels corresponds to chemoresistance, we examined
the toxicity of chemotherapeutic agents in SKUT-1 cells expressing either the control or
Sab shRNAs. We found that silencing Sab made SKUT-1 cells significantly less sensitive
to chemotherapeutic agents (Table 4.3). Thus, the defects in apoptosis corresponded to
diminished chemo-responsiveness in SKUT-1 cells. These data demonstrate that Sab118

mediated signaling is crucial to cell death induction in UC cells and decreased Sab levels
may in part be responsible for the treatment-resistant disease.
Table 4.3. IC50 values for chemotherapy agents in SKUT-1 cells with diminished Sab
expression.

4. Discussion
Late-stage UCs are typified by a poor survival rate; specifically, metastatic UC has only a
16.9% survival [1]. Because the risk factors are commonplace: obesity, high blood
pressure, and diabetes mellitus, it’s important to address the low survival of metastatic
cancer [7]. Our previous work has shown that mitochondrial JNK signaling on the scaffold
protein Sab is a critical mediator of apoptosis in gynecological cancers cells [28, 29].
Furthermore, in Chapter 3, we showed that diminished Sab levels contribute to
chemoresistance in ovarian cancer. Herein, we used patient-derived data and cellular
studies to demonstrate the consequences of diminished Sab-mediated signaling in UC. Our
results demonstrate that Sab expression is down-regulated in UC and restoring Sab levels
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on mitochondria restores apoptotic induction. These studies provides unique insight into
the mechanisms driving resistance in late-stage UC.
Our secondary data analysis of Sab expression in UC patient samples revealed that Sab
mRNA levels were decreased significantly in late-stage and recurrent disease (Figure 4.1).
While this reflects our previous observation in ovarian cancer, we did not segregate the
ovarian patient data into clinical stages nor did we consider recurrence. The late decrease
in Sab transcripts in advanced disease suggests that the change in Sab expression is in
response to the progressive pathology of the disease. Our previous work demonstrates that
mitochondrial JNK signaling, and by extension the expression of Sab, is highly responsive
to mitochondrial toxins [28, 53, 54]. Since mitochondrial dysfunction is necessary for
oncogenesis [55], one can postulate that Sab expression may be diminished as cancer cells
switch to glycolysis and minimize their reliance on mitochondria [56]. Additionally, it is
possible that prolonged mitochondrial dysfunction could habituate stress signaling failing
to recognize mitochondrial damage and activate stress responses like mitochondrial JNK
signaling. Regardless, the transcriptional regulation of Sab in gynecological cancers
remains a topic of active investigation in our group.
To examine the role of Sab-mediated signaling in UC physiology, we employed a primarysite derived cell line (SKUT-1) and a metastatic-derived cell line (AN-3-Ca) to investigate
early and late-stage UC. Initially, we found that AN-3-Ca cells had greater mitochondrial
metabolism than SKUT-1 (Figure 2), which would suggest greater integrity of
mitochondrial membrane potential. This was realized when we discovered that AN-3-Ca
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cells had a higher concentration of Bcl-2 on the mitochondrial surface [57, 58]. This would
suggest that the outer membrane of the mitochondria was more intact than the SKUT-1
cells, which may in part explain the higher levels of respiration. The greater oxidative
potential of metastatic UC cells may also be necessary to generate ROS needed for invasion
[59]. Although we have previously shown that Sab can contribute to ROS amplification
[53], it is likely that the significant levels of uncoupling and proton leak in AN-3-Ca cells
(Figure 2) suggest a level of mitochondrial dysfunction that may be sufficient to generate
the levels of ROS needed for metastasis.
SKUT-1 cells were found to be more glycolytic, which is the hallmark metabolic feature
of cancers [55]. This may also be partly explained by the increased levels of Sab in older
patients. Specifically, in the aging brain, mitochondrial JNK signaling has been shown to
impair the activity of pyruvate dehydrogenase reducing the amount of glucose oxidation
[60, 61]. Alternatively, JNK signaling has been shown to influence a myriad of metabolic
signaling [62]. One mechanism JNK signaling could employ is to phosphorylate Bcl-2
proteins and alter their functions. Bcl-2 proteins have been shown to contribute to
metabolic flux in mammalian cells [63, 64], and altering their mitochondrial functions
could contribute to this outcome.
The predominant impact of diminished Sab levels appears to be on the induction of
apoptosis. UC cells with low Sab levels had increased anti-apoptotic Bcl-2 proteins and
were resistant to chemotherapeutic agents; alternatively, cells with high Sab levels or
restoring Sab levels increased the levels of pro-apoptotic BH3-only proteins on
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mitochondria resulting in greater sensitivity to chemotherapeutic drugs. The specific
change was a decrease in Bcl-2 levels on mitochondria and an increase in Bim and Bid.
These drugs are well-established JNK targets [38], and the manipulation of these proteins
occurs either at mitochondria or via JNK activity on the common scaffold 14-3-3 [65].
Mitochondrial JNK is a potent inducer of apoptosis following cytosolic stress, so increasing
the magnitude of mitochondrial JNK signaling could greatly enhance apoptotic responses
in cancer cells. However, this should be considered with caution, since elevating
mitochondrial JNK signaling can induce off-target effects such as cardiotoxicity of
chemotherapy agents [30]. This is of particular concern in older patients, which is the
largest population of UC patients [3].
These studies demonstrate that diminished Sab-mediated signaling in advanced UC can
contribute to apoptotic resistance. Consequently, the concentration of Sab in tumors could
be used as a prognostic to determine the relative dose of chemotherapy needed to treat a
UC patient; alternatively, therapeutic approaches aimed at increasing Sab-mediated
signaling could be potent chemosensitizing agents if their actions can be limited to cancers
cells. We propose that investigation of Sab in more cells lines and in patient-derived
xenograft models are needed to validate Sab as a prognostic marker or therapeutic target.
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Chapter 5
A HIGH-THROUGHPUT ASSAY TO SCREEN FOR COMPOUNDS
ELEVATING SAB CONCENTRATIONS IN CHEMO-RESISTANT HUMAN
OVARIAN CANCER CELLS.
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1. Introduction
With a mortality rate of approximately 55%, ovarian cancer (OC) is the deadliest
gynecological malignancy due to the high level of recurrent and therapeutic resistant
disease. The risk of developing recurrent OC in a woman’s lifetime is 1 in 79 and risk of
dying from invasive OC is 1 in 109, which highlights the seriousness of OC [1, 2]. Even
though numerous treatments are available for OC, the recurrence and resistance to available
therapies is a substantial problem for effectively treating patients. Thus, there is a need for
more advanced treatments that target the unique aspects of OC biology in recurrent and
resistant cases for complete, efficacious management of OC.
Sab (SH3-binding protein 5, SH3BP5) is an outer mitochondrial scaffold protein that
facilitates signal transduction events at the organelle-cell interface [3, 4]. Specifically, the
interaction between Sab and the c-Jun N-terminal kinase (JNK) leads to inhibition of
mitochondrial respiration, generation of reactive oxygen species, and the onset of
mitochondrial dysfunction [5-7]. The JNK-Sab interaction (Mito-JNK signaling) is a
crucial component of the intrinsic-apoptotic cell death following many toxic insults
including chemotherapy agents [8-11]. Furthermore, inhibiting JNK or selectively
targeting the JNK-Sab interactions protects various cell types from mitochondrial
dysfunction and cell death [5, 6, 12-17]. Chambers et al. demonstrated that interfering with
the JNK-Sab interaction blocks JNK-mediated Bcl-2 phosphorylation and emigration from
the outer mitochondrial membrane [5]. Lastly, in different models of human disease, MitoJNK signaling is essential for mitochondrial dysfunction and apoptosis [5, 6, 12-15, 17].
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Enhanced Mito-JNK signaling has been linked to an increased capacity to induce apoptosis
in cells with elevated Sab concentrations on mitochondria [6, 18]. Thus, increasing Sab
levels was exploited as a strategy to enhance the efficacy of chemotherapeutic agents in
drug-resistant cancer cells. LY294002 is an inhibitor of the PI3K signaling pathway, and
it is used to improve chemotherapeutic efficacy [6, 18]. We observed an increase in Sab
concentrations on the outer mitochondrial membrane with sub-chronic low dose treatment
of LY294002, which caused the increase in the mitochondrial JNK level during stress.
Elevated Sab resulted in a decrease in IC50 values of commonly used chemotherapeutic
drugs, cisplatin, and paclitaxel [18]. However, the concentration of LY294002 was higher
than physiologically-relevant drug concentrations [19]. As discussed in Chapter 3, the level
of Sab expression corresponded to apoptotic priming and drug efficacy in ovarian cancer
(OC) cell lines. Furthermore, we observed that increasing Sab levels enhances proapoptotic Mito-JNK signaling in OC (Chapter 3) and endometrial (Chapter 4) cells.
Clinically, gene expression (microarray) data from the Oncomine repository shows that
Sab expression is diminished significantly in OC tumors compared to normal tissue
controls. The low levels of Sab in patients also corresponded to disease resistance and poor
survival as well. Hence, we propose that therapeutics aimed at increasing Sab levels in
gynecological cancers can be used to improve chemotherapeutic efficacy in treatmentresistant gynecological cancers.
Our studies in OC demonstrate that Sab may be a biomarker for apoptotic priming and
chemo-sensitivity. Small molecules capable of increasing Sab levels in chemoresistant
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cancer cells can render these cells sensitive to established therapies, which represents a
new, innovative venue for treating gynecological malignancies. Molecular target-based
therapy is considered a new approach for designing and prioritizing OC treatments, and
Sab may represent a potential target for these efforts. Moreover, small molecules affecting
Sab expression will provide unique insight into mechanisms of OC resistance and
regulation of mitochondrial physiology and JNK signaling.
To determine if Sab expression could be modulated by small molecules, we developed a
highly-specific and reproducible In-cell western (ICW) assay, a quantitative
immunofluorescence-based technique used to detect protein levels [20], to detect the
relative levels of Sab in chemoresistant OC cells. After determining antibody specificity, a
small panel of 80 compounds was used to identify compounds that induced Sab expression
over 72 hours. We found that mitochondrial toxins and estrogens were the most potent
inducers of Sab expression, while cyclic AMP analogs and inducers of protein kinase A
(PKA) signaling significantly impaired Sab levels. Each compound class was verified in
cell culture with conventional western blot analysis; RT-PCR analysis of Sab expression
did not always correlate to Sab levels. After validation, the ICW was used to screen a
scaffold ranking plate (over 50 compound classes) and a positional scanning library (over
3,000 individual compounds) from the Torrey Pines Institute for Molecular Studies. We
identified seven (7) distinct scaffolds that significantly elevated Sab expression in
chemoresistant SK-OV-3 cells. From the two best scaffold families, we screened over 900
compounds, and more than forty of those compounds increased Sab-expression. Also,
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greater than 20 compounds were robustly lethal to SK-OV-3 and may represent new
therapeutic classes to treat resistant diseases. We propose that the Sab ICW is a robust
approach to survey small molecules for impacts on Sab protein levels in cells.

2. Methods
2.1. Cells and Tissue Culture
Human HeLa, Hek-293T, and HepG2 cells were cultured in Dulbucco’s Minimal Essental
Media (DMEM) containing 10% fetal bovine serum (FBS), 100U/ml Penicillin, 10g/ml
streptomycin and 5g/ml plasmocin. Human SK-OV-3 (ATCC HTB-77) ovarian
carcinoma cells were grown in McCoy’s 5A (Thermo-Fisher Scientific #SH30200.01)
media supplemented with 10% fetal bovine serum (FBS), 100U/ml Penicillin, 100g/ml
streptomycin and 5g/ml plasmocin under normal cell culture conditions (at 37˚C and 5%
CO2). Cells were grown to approximately 80% confluency were trypsinized using TrypLE
Express (Life Technologies #12604-013) and counted with the TC10 cell counter (BioRad) using trypan blue exclusion dye.
2.2 Antibody Validation and Optimization
The Sab monoclonal antibody (Novus Biologics #H00009467-M01) was validated using
cell lines with varying levels of Sab expression. We isolated a HEK-293T clone that did
not express Sab (based on RT-PCR for Sab transcripts), and this line, called HEK-293T381 (“Sab null”), was used as a negative control. Additionally, we used shRNAs (described
in Chapter 3) to reduce Sab-expression; meanwhile, pLOC:Sab was used to increase Sab
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levels in HeLa cells. Western blots were performed on these cell lines to make sure that
the Sab antibody only detected Sab protein in human cells [5, 6, 18].
2.3 In-Cell Western
After optimization of cell number, reagent concentrations, and assay volumes, we
developed the following protocol for the Sab ICW. Black walled clear bottom 96 well plate
(Thermo Scientific #H2861653050) was seeded with a 200l mixture of trypsinized cells
and media, with a count of 20,000 cells per well. Three hours after plating cells were treated
with either 1M of known compounds for 72 hours or 50g/ml for compounds in scaffold
ranking and lead discovery for 16 hours at normal cell culture conditions. Cells were fixed
with 4% paraformaldehyde (Santa Cruz Biotechnology #SC-281692) for 20 minutes at
room temperature (RT).
The cells were quenched with 100mM glycine for 5 minutes at RT. Cells were
permeabilized using phosphate-buffered saline (PBS) with 0.2% Triton X-100, gently
rocking for 20 minutes at RT. After permeabilization, the cells were blocked with 150l of
LI-COR blocking buffer (LI-COR Biosciences, 927-40100), gently rocking the plate for
90 minutes at RT. Sab antibody was diluted in blocking buffer at a ratio of 1:1000 and
100l of this solution was added to each well. The plate was incubated on a rocker for 2.5
hours at RT and then washed with 100l of PBST (PBS+0.1% Tween-20) for 5 minutes
rocking at RT. This was repeated five times. A 1:800 ratio of anti-mouse secondary
antibody (IRDye 800CW anti-mouse, LI-COR Biosciences, 926-32210) and 1:1000 ratio
of 1mM of TO-PRO-3 (Invitrogen) were diluted in blocking buffer to make the secondary
136

antibody solution. Cells were incubated with 100l of secondary antibody solution in each
well for 45 minutes gently rocking at RT. The plate was washed five times with PBST. The
wash buffer was removed, and the plate was scanned in Odyssey scanner, and the protein
expression was quantified using the LI-COR In-cell western analysis in the Image Studio
2.0 (LI-Cor). Compounds that induced robust cell death, as indicated by a complete loss of
TO-PRO-3 fluorescence, were noted, but these compounds were not included in our
analysis of Sab expression. Instead, lethal compounds were checked for toxicity in HEK293T cells to determine if the cell death was selective towards SK-OV-3 cells. A list of
known compounds (and their classifications) used for optimization and primary testing can
be found in Table 5.1.
2.4 Drug Treatments for Validation
To determine if drugs identified in the ICW screen did indeed affect Sab levels in SK-OV3 cells, we plated 2.5x106 SK-OV-3 cells in the wells of two replicate six-well plate. Each
well of the plate was then either left untreated or treated with 0.1% dimethylsulfoxide
(DMSO) or 0.01M, 0.1M, 1M, or 10M of the identified compound. The cells grew in
these conditions for 72 hours.
2.5 Validation of Sab Levels
From the cell cultures described above, one plate was used to harvest RNA according to
the Qiagen RNEasy Kit protocol, and a second plate was lysed and used for traditional
western blot analysis. Cells were lysed, and proteins were quantified according to our
previous studies (see Chapter 3). The RNA was used for RT-PCR analysis to evaluate if
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the compound affected Sab expression, while the cell lysates samples were used to assess
the impact of Sab protein levels. RT-PCR data were normalized to the relative levels of
housekeeping genes, actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
pyruvate kinase (PK), lactate dehydrogenase (LDH), and ATP synthase subunit F1.
Protein levels were normalized to tubulin for cellular analyses, while VDAC was used as
a mitochondrial normalization control. In the absence of another Sab antibody recognizing
a distinct epitope, we used relative JNK translocation to mitochondria to determine if JNK
levels were increased or decreased following particular drug treatments in response to
cytotoxic stress. Briefly, cells were grown in three (3) 150mm 2 plates and exposed to
candidate compounds at a non-toxic dose for 72 hours. The cells were then exposed to
25M Anisomycin for 45 minutes. Mitochondria were isolated using our established
protocol (see references). Mitochondria were lysed using RIPA and analyzed for western
blot analysis for the relative levels of JNK. Results were quantified using the Image Studio
2.0 software.
2.6 Assessment of Cell Viability and Chemotherapeutic Efficacy
We performed dynamic BH3-profiling, determined the IC50 values for cisplatin and
paclitaxel, and assessed relative cell viability using a panel of assays in the presence of
cisplatin/paclitaxel after 72 hours of exposure to the identified compounds to evaluate the
impact on drug efficacy. The methods for measuring IC50 values and cytotoxicity
assessments were described in the previous chapters.
2.7 Statistics
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Cell-based measures and traditional western blotting data were analyzed by performing
Mann-Whitney U Tests for direct comparisons, and analysis of variance was performed to
compared multiple compounds. For studies involving cell-based screening, assay quality
was determined using a Z’ calculation of positive (Sab-overexpressing cells) and negative
controls (Sab-silenced cells) using the equation described in [21]. The Z’ was interpreted
in regards to the coefficient of variation (CV) for specific cells. Only measures with >15%
between basal measures and positive and negative controls were considered for used. Valid
assays parameters were considered those that had a Z’ score >0.675 and CV greater than
50%. Reproducibility was determined between measures using a Tukey post-hoc analysis.

3. Results
3.1 Development of a reliable ICW to detect Sab levels in human cell lines and OC
cells.
To develop our in-cell western (ICW) approach, we selected an antibody previously used
in our lab to monitor Sab levels in cell lysates and tissue homogenates. To be sure that the
antibody would be selective enough for use in a high-throughput screening assay, we
measured the antibodies specificity in cell lines that did not express Sab (HEK-293T-381
– Sab-null), HEK-293T, and HEK-293 cells overexpressing Sab (pLOC:Sab) and silencing
Sab (pLKO.1:shSab). Accordingly, the antibody did not detect the anticipated Sab band
nor any additional bands in the Sab null cells (Figure 5.1). While different levels of Sab
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were found in HEK-293T, and HEK-293T cells with increased and decreased Sab
expression (Figure 5.1). COX-IV was used to demonstrate equal loading
of mitochondrial

Figure 5.1: Validation of the Sab-specific antibody for assay development A western blot
analysis of HEK-293T cells was performed with an antibody (Novus Biologicals) specific for
human Sab. The HEK-293T cells were transfected with plasmids for silencing Sab (pLKO:shSab),
which expressed a Sab shRNA, and pLOC:Sab, a plasmid that over-expressed Sab. A HEK-293T
clone that did not express Sab (Sab null) was used as a negative control. An extended membrane
image is presented to demonstrate the minimal non-specific binding of the antibody. COX-IV was
used as a mitochondrial loading control, while Ponceau S was used to demonstrate equal loading
among cell types.

Proteins and Ponceau staining of membranes were used as a loading control (Figure 5.1).
After validating the reliability of the antibody, we optimized cell conditions to develop an
assay that provided a sufficient dynamic range between Sab null and Sab overexpressing
HEK-293T cells. In Figure 5.2, we demonstrate the signal distribution of the in-cell western
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in the different HEK-293T types. The assay has a dynamic range of 10-fold on a log scale
which is a large dynamic range for a high-throughput assay.

Figure 5.2: Optimizing the ICW for detection of distinct levels of Sab in cells. (top panel) The
ICW was performed in a 96-well plate, and the Sab-related fluorescence was determined using the
Odyssey CLx imager. Repeated measures (20) were performed for each cell type with 16 blank
wells. (Bottom panel) Sab fluorescence distributions were plotted for each condition, and a Z’ score
was calculate to be 0.76 between Sab-null and normal HEK-293T cells suggesting a strong assay.

3.2 Pilot studies reveal that mitochondrial toxins and estrogens increase Sab
expression.
To determine if Sab levels could be manipulated by pharmacological agents, we used a
small pool (62) of compounds from the LOPAC 1280 library that were known to impact
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mitochondrial physiology and cellular kinase cascades to examine to impact on Sab levels.
We plated 12,000 HEK-293T cells in a 96-well plate and treated with compounds at a 10fold dilution from manufacturer’s preparation. We performed the ICW at 72 hours posttreatment. The data were analyzed, and Sab-fluorescence was normalized to viable cells

Figure 5.3: A preliminary screen to examine Sab levels following pharmacological
treatments. (left) Normalized Sab fluorescence was plotted, and the relative change with respect
to controls was plotted on a volcano plot. Assay controls for Sab-expression, such as overexpression, silencing, and JNK inhibitors are highlighted. (right) A table summarizing the
compounds that increased and decreased Sab levels in HEK-293T cells. The P-value and pathways
are noted to the right of the compound effect ratio.

by TO-PRO-3 staining. The data were plotted on a volcano plot to observe Sab
concentration trends (Figure 5.3).
The compounds responsible for the accumulation of Sab in cells were mitochondrial toxins,
such as antimycin and benzo[]pyrene, and inflammatory compounds, like TNF-.
Alternatively, antioxidants were found to decrease Sab levels in cells. Intriguingly,
estrogen metabolites were also found to decrease Sab levels. Intriguingly, PKA modulators
were potent effectors of Sab levels; wherein, inhibition of PKA by H89 increased Sab
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concentrations, while activation of PKA by forskolin decreased Sab levels. This
preliminary screen indicated that the ICW is a valid tool to detect changes in Sab abundance
in cells and identify compounds that affect Sab concentrations.

Figure 5.4: A redeveloped ICW for Sab detection in chemoresistant SK-OV-3 cells. (left) A
representative validation assay for SK-OV-3 cells. (right) The Z’ score calculation for four (4)
replicate assay. A high Z’ score of 0.8156 was achieved indicating a strong assay.

3.3 Examination of the scaffold ranking library from Torrey Pines Institute for
Molecular Studies (TPIMS). To identify compounds that could increase Sab levels in
chemoresistant OC cells, we re-optimized the assay for SK-OV-3 cells (see Chapter 3).
The redeveloped assay is shown in Figure 5.4.
To determine if pharmacological agents could increase Sab levels in SK-OV-3 cells, we
took the most potent Sab enhancers from our preliminary screen and used those molecules
to assess the feasibility of elevating Sab in resistant OC cells. In Figure 5.5, H89,
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LY294002, antimycin, rotenone, oligomycin, and hydrogen peroxide (H 2O2) were exposed
to SK-OV-3 cells at increasing doses for up to 72 hours, and the Sab ICW was performed.
All of the compounds except oligomycin increased Sab expression in SK-OV-3 cells
(Figure 5.5). This result confirms that Sab levels can be increased by pharmacological
agents in SK-OV-3 cells.

Figure 5.5: A feasibility screen for detecting changes in Sab levels in SK-OV-3 cells. (left) A
representative assay in SK-OV-3 cells using compounds known to enhance Sab levels in HEK293T cells. We plated 15,000 cells per well and treated them with increasing concentrations of
drugs for up to 72 hours. The Sab ICW was performed after treatment. (right) The quantification
of three replicate assays was performed with Sab fluorescence normalized to TO-PRO-3 staining.
One-way ANOVAs were performed to identify significant differences as indicated by an *
(P<0.05). Data are displayed as means with error bars representing plus and minus one standard
deviation.

Next, we utilized a scaffold-ranking and positional-scanning library from the Torrey Pines
Institute for Molecular Studies (TPIMS, Port St. Lucie, FL) to identify new compounds
that could increase Sab concentrations in chemoresistant OC cells. We screened ~50
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scaffold families in a randomized plate from TPIMS. We plated the cells and treated with
compound families from TPIMS for 48 hours and applied the Sab ICW. Two separate
screens were performed per batch (Figure 5.6A), and after the assay we applied our
statistical parameters to identify prospective compound families (Figure 5.6B & 5.6C).

Figure 5.6: A scaffold ranking screen and compound criteria for the TPIMS library. (A) A
representative screen in SK-OV-3 cells using compounds from TPIMS. We plated 15,000 cells per
well and treated them with increasing concentrations of drugs for 48 hours. The Sab ICW was
performed after treatment. (B) The quantification criteria for assessing Sab levels and (C) viability
by TO-PRO-3 staining.

The screen netted seven (7) compound families that could be viable compounds for
elevating Sab expression in chemoresistant OC cells. We took those compounds and we
assayed the compounds in the ICW to validate the compounds as Sab inducers. In Figure
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5.7, the secondary screen is shown, and a spaghetti plot shows that one group elevated Sab
expression significantly, and that family was 1661, suggesting it may be a useful
chemosensitizer.

Figure 5.7: A positional scanning screen to identify best-in-class compounds from the TPIMS
library. (left) A representative screen in SK-OV-3 cells using compound families from TPIMS.
We plated 15,000 cells per well and treated them with increasing concentrations of drugs for 48
hours. The Sab ICW was performed after treatment. (right) Quantification of the assay illustrates
the increase with Sab fluorescence in response drug dose.

Lastly, we evaluated family 1661 in SK-OV-3 cells to determine if the compound elevated
Sab and to assess the impact on viability. We performed a dose-dependent ICW for
compound family 1661, and we found that the compound family did increase Sab
expression in a dose-dependent manner and had limited impact on viability in a
physiologically relevant dose range (Figure 5.8A). These measures are quantified in Figure
5.8B. We then treated SK-OV-3 with 1661 at increasing concentrations in two replicate
preparation from TPIMS. In these studies (Figure 5.8C), Sab levels increase in a dosedependent manner without impacting mitochondrial protein concentration (indicated by
COX-IV levels). Ponceau staining was used as a loading control. These results demonstrate
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that family 1661 could be a potent enhancer of Sab protein levels in chemoresistant OC
cells or OC tumors.

Figure 5.8: Evaluation of family 1661 in SK-OV-3 cells. A. Dose-dependent ICW for family
1661. B. Quantification of A. C. SK-OV-3 cells were treated with increasing dose of compound
family 166. Sab level increases in a dose-dependent manner. Data are displayed as means with error
bars representing plus and minus one standard deviation.

4. Discussion
The ability to predict tumor-specific vulnerabilities to therapeutic regimes will be an
invaluable resource aiding personalized medical efforts, and such technologies will
improve patient outcomes associated with ovarian cancer. In the current work, we describe
a high-throughput technique to quantify the Sab concentrations in human cell lines with
the aim of identifying compounds capable of increasing Sab levels to improve
chemotherapeutic efficacy. This approach has many advantages over traditional way to
quantify protein expression. Western blotting has been used as a major approach to
quantify protein expression; however, this high-throughput ICW is advantageous over low-
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throughput WB. WB is labor-intensive and time-consuming. There is a requirement of
more resources, i.e., more cells and more compounds or drugs, however, with this
approach, the experiment can be done in one well of a microplate, which saves time and
resources. There is a 100-fold decrease in volume in micro-plate compared to the
experiment done in Petri-dishes [20]. As we have screened scaffold of compounds, this
approach was very useful for detection of Sab-level. During western blotting, while lysing
the cells, we use different detergents, and this might interfere with the protein detection,
however, in ICW assay we detect the protein within the cell without interfering with its
expression. With the fixation step, there might be a change in fluorescence signal. We used
4% PFA in PBS with less fluorescence property [20]. We also experimented without using
the fixation agent and didn’t observe a significant difference in fluorescence signal with or
without fixation. The approach that we developed uses TO-PRO-3 for antibody
normalization which is a preferred method [22]. TO-PRO-3 is a DNA staining dye and is
used to normalize the number of cells. TO-PRO-3 stains the live cells, hence it also detects
the cytotoxicity of the compound under screening. Because of the availability of two
separate lasers and two different fluorescence channel in Odyssey Imager, we could detect
two different targets, the antigen of our interest (Sab) and TO-PRO-3 dye. The fluorescent
antibody is detected at 800nm channel while the TO-PRO-3 stain is detected at 700nm
channel. The emission spectra are separated by 100nm, showing minimum interference in
the signal.
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As suggested by Chen et al., antibody specificity is critical for validation of ICW assay.
We observed a single band of Sab in western blotting, showing the specificity of Sab in
SKOV-3 cells [22]. The antibody is highly specific, as we do not see any alternate bands
(Figure 5.1), which makes it an ideal candidate for assay development. More importantly,
the specificity of the antibody provided an opportunity for a large dynamic range (Figure
5.2). This 10-fold change will permit the identification of robust as well as modest
modulation of Sab concentrations in cells, which will be essential to elucidate the
regulation of Sab in different tissues and cell types. More importantly, a range of effective
compounds can be identified for use in OC studies; whereby, a modest, non-toxic
adjustment in Sab levels may be required to restore apoptotic capacity.
The demonstration that Sab levels could be altered by pharmacological agents was crucial
to establishing our assay (Figures 5.3 and 5.5) because if we could not manipulate Sab with
chemicals, the only other option would be through gene therapy approaches, which are not
ready for clinical use. It was interesting that manipulation of PKA signaling had such a
profound effect on Sab levels. This observation is interesting in part because mitochondrial
PKA signaling has been shown to sustain mitochondrial health and improve cell survival
[23-28]. These are the opposite effects of mitochondrial JNK signaling. It is interesting to
conjecture that protective PKA signaling may post-translationally impair detrimental Sabmediated events in human cells. Alternatively, enhanced Sab mediated signaling may be
required to disengage the protection of PKA in apoptotic cells. The relationship of these
two signaling pathways is ongoing in our lab.
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A potent enhancer of Sab levels were mitochondrial toxins. Indeed, we have shown that
mitochondrial JNK signaling is responsive to mitochondrial stress and JNK signaling
regulates Sab expression [7, 18]. This data suggests that the upregulation of Sab following
mitochondrial damage may be a stress response rather than an abortive mechanism.
Similarly, TNF-a is a potent activator of JNK signaling during inflammation, and JNK is
responsible for activation transcriptional responses in immune responses; however, the role
of mitochondrial JNK is this regard is still unknown [29]. Further studies will be needed to
determine the physiological role of mitochondrial JNK signaling on Sab.
The presence of estradiol as a negative regulator of Sab levels was equally interesting
because estrogen has been shown to regulate AP-1 transcription, a target activated by JNK.
Also, estrogen has been shown to prevent neurodegeneration in Parkinson’s models where
our work has demonstrated that Sab-mediated JNK signaling drives neuron loss in the
substantia nigra [15, 30-32]. Alternatively, estrogen has been shown to induce JNKmediated apoptosis in cancer cells [33, 34]. It is likely the impact of estrogen signaling on
JNK-mediated processes will be cell type and tissue-specific; thus, elucidating the impact
of estrogen signaling on Sab levels in OC cells will be important since estrogen can be used
as hormone therapy in gynecological cancers [35-37].
We used this technique to screen the compounds that could increase Sab expression in
SKOV-3 cells. As mentioned previously, increasing Sab expression sensitizes the cancer
cells for chemotherapeutic agents [18]. We were looking for compounds that would
increase the Sab expression with less cytotoxic effect, eventually causing less harm to
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normal cells (Figure 7). Our screening strategy was to find the compounds that would
increase the Sab expression by 30% with least effect on the viability of the cells. As shown
in Figure 5.4, the assay was highly reproducible with the screening of same compounds.
We identified a compound family 1661 that will be the topic of ongoing development for
use in preclinical OC models. Regardless of the outcome of 1661, we have developed an
assay that can be used to screen existing chemical as possible agents to improve
chemotherapeutic efficacy in chemoresistant OC cells.
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Chapter 6
CONCLUSION
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The goal of this research project was to identify and characterize molecular events
responsible for therapeutic resistance in gynecological cancers. Our rationale was that once
mechanisms driving resistance and recurrence are known therapeutic approaches can be
developed to target these events. Our previous research has focused on how changes in
mitochondrial signaling influence the susceptibility of mammalian cells toward cytotoxic
stimuli. Specifically, we have reported that increasing Sab-mediated signaling sensitizes
cells to stressors in a JNK dependent manner. The result of this change in mitochondrial
signaling is a lower threshold for the induction of apoptosis. Thus, we hypothesized that
diminished Sab expression in gynecological cancers might contribute to chemotherapeutic
resistance in late-stage disease. To see if this was the case, we examined gene expression
data from patients and manipulated Sab expression in ovarian and uterine cancer cells to
determine how Sab-mediated events impacted the chemoresponsiveness of cancer cells.
Ultimately, we found that decreased Sab levels in gynecological cancer cell lines prevent
proper induction of apoptosis, and restoring Sab levels resulting in improved
chemosensitization. Finally, we used a high-throughput approach to identify
pharmacological agents capable of increasing Sab levels in chemoresistant ovarian cancer
cells. Future studies will revolve around elucidating the impact of Sab levels on
gynecological cancers in preclinical models.
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A summary of the primary findings from each of the project aims can be found below.

First, we identified a decrease in Sab expression using microarray data obtained from
ovarian cancer patient tumors. Ovarian cancer cell lines were obtained and characterized
based on the relative abundance of Sab and the relative responsiveness to chemotherapeutic
drugs. We found that the cell lines expressing low levels of Sab were resistant to these
chemotherapeutic drugs while the cell lines with a high level of Sab showed responsiveness
to chemotherapeutic drugs. Sab levels were then manipulated by ectopic expression or gene
silencing, which changes the magnitude of mitochondrial JNK signaling in ovarian cancer
cells. Cells expressing a high level of Sab are primed for apoptosis, which means these
cells have a higher level of pro-apoptotic BH3-only proteins and low level of anti-apoptotic
Bcl-2 proteins. Hence our result suggests, Sab level reflects the concentration of BH3 only
proteins. Dynamic BH3-profiling can determine chemoresponsiveness in cancer cells. Sab
profiling along with dynamic BH3-profiling can be used as a combined approach to predict
chemoresponsiveness in the ovarian cancer patient.

Second, we examined the impact of Sab levels on chemosusceptibility in uterine cancer.
Analysis of patient samples revealed that Sab expression was diminished in advanced and
recurrent uterine cancers. We used two different cell lines; a primary-site derived cell line
with high Sab levels and a metastatic-derived cell line with low Sab expression. We
assessed mitochondrial physiology and apoptotic capacity in these cells and found that low
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Sab concentrations in the metastatic cell line corresponded to elevated respiration and
proton leak, which was accompanied by elevated levels of anti-apoptotic Bcl-2 proteins.
Uterine cancer cells with elevated Sab concentrations were more glycolytic and had a
greater abundance of pro-apoptotic BH3-only proteins. Like ovarian cancer cells, uterine
cancer cells with a higher level of Sab were sensitive to chemotherapeutic drugs and had
higher expression of pro-apoptotic BH3 only proteins.

Finally, we surmised that pharmacological agents capable of elevating Sab concentrations
could be used to prime gynecological cancer cells for apoptosis and lower the dose of
chemotherapy. Not only could this approach improve the effectiveness of existing drugs,
but the lower dose would mean that there would be less of a chance for off-target toxicity.
To identify chemicals capable of increasing Sab in resistant cancer cells, we developed an
in-cell western method to detect the relative abundance of Sab cancer cells. The approach
was validated in HEK-293T cells where it was found that mitochondrial toxins and
inhibitors of PKA were potent enhancers of Sab levels. The in-cell western was then
applied to chemoresistant ovarian cancer cells and screened against a scaffold ranking
library from the Torrey Pines Institute for Molecular Studies. We found promising
compounds capable of increasing Sab levels in SK-OV-3 cells. Thus, the Sab in-cell
western can be used as a method of screening compounds for novel therapies or to
determine the relative responsiveness of patient cancers to specific therapies. Detecting the
level of Sab in patients’ tumor would help to determine the dose and efficacy of
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chemotherapeutic drugs. We propose this technique can be a useful tool in personalized
medicine.

The main limitation of our study is the use of cell lines instead of patient-derived tumors.
The cell lines might not be representative of tumor cells from patients. Cell lines may
develop additional mutations during adaptation to culture conditions, and additional
genetic variations (i.e., epigenetic changes) not representative of the real cancer cells.
Additionally, the cell lines used in our studies were from different patients and distinct
genetic backgrounds. These difference may also explain the differences in Sab-levels rather
than mechanisms responsible for oncogenesis; likewise, these discrete differences among
cell lines may also explain the susceptibility to chemotherapeutic agents. Thus, increasing
Sab levels may be a means to lower the chemosensitivity of all cells and the phenomenon
may not be specific to gynecological cancers. Further, recent studies preliminarily conclude
that stem cells within tumors may be responsible for chemoresistance. Because we did not
use stem cells from gynecological tumors, we may have missed other factors contributing
to chemoresistance. Thus, future studies will focus on the isolation and characterization of
chemoresponsiveness from patient-derived samples.

Another concern is that increasing Sab levels in cells of distinct genetic background all
enhanced the responsiveness of cells to chemotherapy agents. When viewed in light of our
studies in cardiomyocytes demonstrating that increasing the levels of Sab enhances the
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effect of toxic exposures, it appears as though increasing Sab levels could lower the
apoptotic threshold for all cell types. This means that, if compounds were found that could
increase Sab levels in gynecological cancers, the drugs would have to be selectively
targeted to cancer cells to avoid off-target toxicities. This highlights the importance of
characterizing Sab-mediated signaling in many tissues before delivering potential therapies
to patients.

Another pitfall of our study is the sample size, for ovarian cancer study we have used four
cell lines while for uterine cancer study only two cell lines. The number of cell lines is too
small to derive any true conclusions regarding Sab-mediated signaling and
chemoresistance in gynecological cancers. Again, future studies with more cell types of
appropriate origins will be needed to ascertain the true relevance of Sab-mediated signaling
changes in gynecological cancers.

Despite the limitations of the current study, our study opens a new avenue for connecting
Sab-mediated OMM signaling to the physiology, prognosis, and treatment of
gynecological cancers.

In closing, we have found that Sab levels indicate the relative apoptotic capacity in
gynecological cancer cells and increasing Sab levels represents a unique approach to
improve therapeutic outcomes in patients.
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Appendices
Supplementary Information for Chapter 3
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SUPPLEMENTAL FIGURE 1: Sab is not present in non-mitochondrial subcellular
fractions from OC cell lines.

SUPPLEMENTAL FIGURE 2: Quantification of Phospho-JNK and JNK levels on
untreated and STS-treated OC cell lines.

SUPPLEMENTAL FIGURE 3: Anisomycin stress induces mitochondrial JNK
translocation, and demonstrates differences in mitochondrial JNK signaling among
the four OC cell lines.

SUPPLEMENTAL FIGURE 4: TO-PRO-3 Assays were used to determine cellular
IC50 values for chemotherapeutic drugs.

SUPPLEMENTAL FIGURE 5: Correlation plots of IC 50 values for the four OC cell
lines.

SUPPLEMENTAL FIGURE 6: Quantification of Bcl-2 and BH3-only western
analysis of OC Cell Lines.

SUPPLEMENTAL FIGURE 7: Ectopic Expression of Sab in SK-OV-3 cells does
not impact the cellular apoptosis profile.
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Supplemental Figure 6
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Supplemental Figure 7
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